(A company incorporated with limited liability as an open-ended umbrella investment company with variable capital under the laws of Ireland)

UNAUDITED INTERIM FINANCIAL STATEMENTS FOR THE FINANCIAL PERIOD 1 JANUARY 2021 TO 30 JUNE 2021

Registration No. 489443

SECTOR CAPITAL FUNDS PLC Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

TABLE OF CONTENTS

	Page
eneral Information	2
vestment Managers' Reports	3
alance Sheet	4
ofit and Loss Account	6
atement of Changes in Net Assets attributable to holders of Redeemable Participating Shares	8
hedule of Investments	10
otes to the Financial Statements	12
gnificant Portfolio Movements	. 39

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

GENERAL INFORMATION

Directors

Michael Boyce (*Irish*)^ Lars Tell (*Swedish*) Conor Walsh (*Irish*)^

^Independent non-executive Director

Investment Manager

Harvest Funds AS (resigned 5 February 2021)

Kongens gate 12 N-0153 Oslo Norway

Investment Manager

Sector Funds Services AS (appointed 5 February 2021)

Kristian Augusts gate 15 C

N-0164 Oslo Norway

Investment Manager

Sector Healthcare Value Fund

Sector Gamma AS

Kristian Augusts gate 15 c

N-0164 Oslo Norway

Administrator, Registrar and Transfer Agent

BNY Mellon Fund Services (Ireland) Designated Activity

Company Riverside Two

Sir John Rogerson's Quay

Grand Canal Dock

Dublin 2 Ireland

Depositary

The Bank of New York Mellon SA/NV, Dublin Branch

Riverside Two

Sir John Rogerson's Quay Grand Canal Dock

Dublin 2

Ireland

Company Secretary

MFD Secretaries Limited 32 Molesworth Street

Dublin 2

Ireland

Registered Office

32 Molesworth Street

Dublin 2

Ireland

Independent Auditors

Deloitte Ireland LLP

Chartered Accountants and Statutory Audit Firm

Deloitte & Touche House

Earlsfort Terrace

Dublin 2

Ireland

Legal Advisers to the Company (advisers as to Norwegian law)

BAHR

Advokatfirmaet BAHR AS

Tjuvholmen allé 16

NO-0252 Oslo

Norway

Legal Advisers to Harvest Funds AS (advisers as to Norwegian law)

Thommessen

Haakon Vlls gate 10

Postboks 1484 Vika

NO-0116 Oslo

Norway

Legal Advisers to the Company (advisers as to Irish law)

Maples Group

75 St. Stephen's Green

Dublin 2

Ireland

Sponsoring Brokers

Maples Group

75 St. Stephen's Green

Dublin 2

Ireland

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

INVESTMENT MANAGERS' REPORT

Sector Healthcare Value Fund

The global healthcare sector, as measured by the MSCI World Healthcare Index, returned nearly 10% during the first half of 2021. Relative to the broader equity markets, as measured by the MSCI World Index, healthcare stocks underperformed by 3.4% as more cyclical sectors in the market outperformed.

The Sector Healthcare Value Fund returned 9.3% in the first half of 2021. On a single-stock basis, performance was driven by Gilead, Bruker, Glaxo and Pfizer. The largest losses were represented by Ionis, Morphosis, Organon and Phillips. Style factors, led by growth/value, were a tailwind in the first quarter and a headwind in the second quarter. Relative to the MSCI World Healthcare Index, the Fund underperformed by 60bps.

Despite solid absolute returns in the Fund, the relative performance has been unsatisfactory during the last few years. A multi-year bull market for growth and momentum stocks, have resulted in a bifurcated healthcare universe in terms of performance and valuations. Spreads between cheap and expensive companies are high by historical standards. The current portfolio is attractively valued both on an absolute and relative basis and we believe the long-term growth potential is underestimated.

Sector Gamma AS August 2021

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

BALANCE SHEET

As at 30 June 2021

	Note	Harvest Equity Kernel USD	Sector Healthcare Value Fund USD	Sector Sigma Nordic Fund NOK	Sector Capital Funds Plc USD
Current Assets					
Investments in financial assets held at fair value through					
profit or loss		_	486,568,316	_	486,568,316
Cash at bank and brokers	6	12,869	7,910,703	_	7,923,572
Interest receivable		_	30	_	30
Dividends receivable		4,538	825,017	_	829,555
Other assets	_	892	8,615	_	9,507
Total Assets	_	18,299	495,312,681	_	495,330,980
Current Liabilities Investments in financial liabilities held at fair value					
through profit or loss		_	6,726,131	_	6,726,131
Payable for securities purchased		_	688,350	_	688,350
Subscriptions received in advance		_	765,546	_	765,546
Payable to investment manager	9	14,229	398,274	_	412,503
Incentive fee/performance fee	10	_	323,066	_	323,066
Administration fee	11	_	86,847	_	86,847
Directors' fees and expenses	12	_	10,293	_	10,293
Auditors' fee		_	6,659	_	6,659
Depositary/Custodian fee	11	_	13,151	_	13,151
Legal fee		_	14,495	_	14,495
Equalisation credit payable		_	3,536,165	_	3,536,165
Trading and Research fees		_	4,853	_	4,853
Other creditors		4,070	44,381	_	48,451
Total Liabilities (excluding net assets attributable	. –	,	//		
to holders of Redeemable Participating Shares)	_	18,299	12,618,211		12,636,510
Net assets attributable to holders of Redeemable Participating Shares	20 _	-	482,694,470	-	482,694,470

Harvest Equity Kernel ceased trading on 15 January 2021. Effective 21 May 2021, Sector Sigma Nordic Fund's authorisation was revoked by the Central Bank of Ireland.

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

BALANCE SHEET (Continued)

As at 30 June 2020

	Note	Harvest Equity Kernel USD	Sector Healthcare Value Fund USD	Sector Sigma Nordic Fund NOK	Sector Capital Funds Plc USD
Current Assets					
Investments in financial assets held at fair value through					
profit or loss		116,752,877	213,363,238	_	330,116,115
Cash at bank and brokers	6	16,321,653	112,111	899,643	16,526,568
Interest receivable		755	1,452	_	2,207
Dividends receivable		132,390	395,167	_	527,557
Other assets	_	86,094	5,984	-	92,077
Total Assets	_	133,293,769	213,877,952	899,643	347,264,524
G 41:199					
Current Liabilities Investments in financial liabilities held at fair value					
through profit or loss		807,557	610,002	_	1,417,559
Bank overdraft	6	-	373,217	_	373,217
Subscriptions received in advance	U	153,410	112,111	_	265,521
Payable to investment manager	9	135,327	211,145	_	346,472
Incentive fee/performance fee	10	_	505,168	_	505,168
Administration fee	11	62,317	57,752	_	120,069
Directors' fees and expenses	12	3,395	3,808	_	7,203
Auditors' fee		5,865	6,633	_	12,498
Depositary/Custodian fee	11	8,884	12,265	_	21,149
Legal fee		7,647	5,494	12,460	14,426
Interest payable		3,784		12,100	3,784
Payable to Shareholders		5,701	_	887,183	91,519
Equalisation credit payable		_	3,039,193	007,105	3,039,193
Trading and Research fees		194,361	19,397	_	213,758
Other creditors		210,142	37,078	_	247,220
	_	210,142	37,076		247,220
Total Liabilities (excluding net assets attributable	•	1 200 220	4.072.066	000 (42	6.464.000
to holders of Redeemable Participating Shares)	_	1,398,328	4,973,866	899,643	6,464,998
Ni A construction of the Acids Acids and C. D. J. Const.					
Net assets attributable to holders of Redeemable		121 005 444	200 004 007		240 500 525
Participating Shares	20	131,895,441	208,904,086	-	340,799,527

Sector Sigma Nordic Fund ceased trading on 27 April 2018 and is translated in the Company total column at the Balance Sheet exchange rate of 0.1032. Effective 21 May 2021, Sector Sigma Nordic Fund's authorisation was revoked by the Central Bank of Ireland.

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

PROFIT AND LOSS ACCOUNT

For the financial period 1 January 2021 to 30 June 2021

	Note	Harvest Equity Kernel USD	Sector Healthcare Value Fund USD	Sector Sigma Nordic Fund NOK	Sector Capital Funds Plc USD
Income					
Dividend income		74,355	5,017,202	_	5,091,557
Interest income		3,016	576	_	3,592
Other income	_	5,160	27,033	_	32,193
	_	82,531	5,044,811	_	5,127,342
Net realised gain/(loss) on:					
- investments		25,027,417	23,573,242	_	48,600,659
- foreign currency		4,733,432	13,145,796	_	17,879,228
Net change in unrealised appreciation/(depreciation) on:					
- investments		(21,230,244)	16,635,026	_	(4,595,218)
- foreign currency		(4,693,991)	(15,665,395)	_	(20,359,386)
Net investment gain	-	3,919,145	42,733,480		46,652,625
8	-	, ,	, ,		, ,
Expenses					
Management fee	9	(27,604)	(2,148,602)	_	(2,176,206)
Incentive fee/performance fee	10	_	(21,130)	_	(21,130)
Administration fee	11	_	(234,213)	_	(234,213)
Depositary/Custodian fee	11	(6,812)	(79,545)	_	(86,357)
Directors' fees and expenses	12	_	(15,641)	_	(15,641)
Auditors' fee		(8,455)	(6,531)	_	(14,986)
Legal fee		_	(62,897)	_	(62,897)
Listing fee		(1,266)	_	_	(1,266)
Trading and research fees		_	(62,314)	_	(62,314)
Other expenses		(27,413)	(92,357)	_	(119,770)
Total expenses before waivers		(71,550)	(2,723,230)	_	(2,794,780)
Net expenses after waivers		(71,550)	(2,723,230)	-	(2,794,780)
Net gain before finance costs	-	3,847,595	40,010,250	-	43,857,845
Finance costs					
Interest expense		(20,050)	(1,742)	_	(21,792)
Total finance costs	-	(20,050)	(1,742)	-	(21,792)
	-				
Taxation		(20.252)	(025.00.0		(05/ 5/5)
Withholding tax and other taxation Net increase in net assets attributable to holders of	-	(20,362)	(835,904)		(856,266)
Redeemable Participating Shares resulting from					
operations		3,807,183	39,172,604	_	42,979,787

There are no recognised gains or losses for the financial period other than those set out in the Profit and Loss Account. All activities relate to continuing operations except for Sector Sigma Nordic Fund which ceased trading on 27 April 2018 and Harvest Equity Kernel which ceased trading on 15 January 2021. Effective 21 May 2021, Sector Sigma Nordic Fund's authorisation was revoked by the Central Bank of Ireland.

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

PROFIT AND LOSS ACCOUNT (Continued)

For the financial period 1 January 2020 to 30 June 2020

	Note	Harvest Equity Kernel USD	Sector Healthcare Value Fund USD	Sector Sigma Nordic Fund NOK	Sector Capital Funds Plc USD
Income					
Dividend income		1,081,935	1,877,920	_	2,959,855
Interest income		56,029	35,994	_	92,023
Other income	_	2,611	461,472	_	464,083
	_	1,140,575	2,375,386	_	3,515,961
Net realised gain/(loss) on:					
- investments		(3,025,393)	9,253,861	_	6,228,468
- foreign currency		(7,572,709)	(5,987,402)	_	(13,560,111)
Net change in unrealised appreciation/(depreciation) on:					
- investments		(661,483)	(9,818,115)	_	(10,479,598)
- foreign currency		(1,256,824)	(2,041,026)	_	(3,297,850)
Net investment loss	-	(11,375,834)	(6,217,296)	_	(17,593,130)
	-				
Expenses		(225.5.45)	(1.105.554)		(1.451.101)
Management fee	9	(335,547)	(1,135,554)	_	(1,471,101)
Incentive fee/performance fee	10	(00,002)	106,438	_	106,438
Administration fee	11	(98,893)	(127,362)	_	(226,255)
Depositary/Custodian fee	11	(36,930)	(46,615)	_	(83,545)
Directors' fees and expenses	12	(5,324)	(7,820)	_	(13,144)
Auditors' fee		(3,407)	(4,144)	_	(7,551)
Legal fee		(14,546)	(15,303)	_	(29,849)
Listing fee		(2,197)	(3,195)	_	(5,392)
Trading and research fees		(178,967)	(28,336)	_	(207,303)
Other expenses	-	(46,603)	(60,210)	_	(106,813)
Total expenses before waivers		(722,414)	(1,322,101)	_	(2,044,515)
Net expenses after waivers		(722,414)	(1,322,101)	-	(2,044,515)
Net (loss) before finance costs	<u>-</u>	(12,098,248)	(7,539,397)	-	(19,637,645)
Finance costs					
Interest expense		(70,023)	(1,592)	_	(71,615)
Total finance costs	-	(70,023)	(1,592)	_	(71,615)
Town Minnies Costs	-	(10,020)	(1,074)		(/1,013)
Taxation		(207.720)	(001.065)		(565,105)
Withholding tax and other taxation Net decrease in net assets attributable to holders of	-	(285,520)	(281,965)		(567,485)
Redeemable Participating Shares resulting from					
operations	=	(12,453,791)	(7,822,954)	_	(20,276,745)

There are no recognised gains or losses for the financial period other than those set out in the Profit and Loss Account. All activities relate to continuing operations except for Sector Sigma Nordic Fund which ceased trading on 27 April 2018 and Harvest Equity Kernel which ceased trading on 15 January 2021. Effective 21 May 2021, Sector Sigma Nordic Fund's authorisation was revoked by the Central Bank of Ireland.

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

STATEMENT OF NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE PARTICIPATING SHARES

For the financial period 1 January 2021 to 30 June 2021

	Harvest Equity Kernel USD	Sector Healthcare Value Fund USD	Sector Sigma Nordic Fund NOK	Sector Capital Funds Plc USD
Net Assets attributable to holders of Redeemable Participating Shares at beginning of the financial period	124,692,469	367,309,862	_	492,002,331
Capital transactions:				
Issue of Redeemable Participating Shares	629,011	109,689,805	_	110,318,816
Redemption of Redeemable Participating Shares	(129,128,663)	(32,580,518)	_	(161,709,181)
Equalisation applied	_	(897,283)	_	(897,283)
Net (decrease)/increase in net assets resulting from capital transactions of Redeemable Participating		, , ,		<u>, , , , , , , , , , , , , , , , , , , </u>
Shares	(128,499,652)	76,212,004		(52,287,648)
Net increase in net assets attributable to holders of Redeemable Participating Shares resulting from operations	3,807,183	39,172,604		42,979,787
Net Assets attributable to holders of Redeemable Participating Shares at end of the financial period	-	482,694,470	_	482,694,470

Harvest Equity Kernel ceased trading on 15 January 2021. Effective 21 May 2021, Sector Sigma Nordic Fund's authorisation was revoked by the Central Bank of Ireland.

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

STATEMENT OF NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE PARTICIPATING SHARES (Continued)

For the financial period 1 January 2020 to 30 June 2020

	Harvest Equity Kernel USD	Sector Healthcare Value Fund USD	Sector Sigma Nordic Fund NOK	Sector Capital Funds Plc USD
Net Assets attributable to holders of Redeemable Participating Shares at beginning of the financial period	127,320,414	167,225,950	=	294,546,364
Capital transactions:				
Issue of Redeemable Participating Shares	27,821,583	80,850,809	_	108,672,392
Redemption of Redeemable Participating Shares	(10,792,765)	(30,609,566)	_	(41,402,331)
Equalisation applied	_	(740,153)	_	(740,153)
Net increase in net assets resulting from capital				<u> </u>
transactions of Redeemable Participating Shares	17,028,818	49,501,090		66,529,908
Net decrease in net assets attributable to holders of Redeemable Participating Shares resulting from operations	(12,453,791)	(7,822,954)	-	(20,276,745)
Net Assets attributable to holders of Redeemable				
Participating Shares at end of the financial period	131,895,441	208,904,086	_	340,799,527

Sector Sigma Nordic Fund ceased trading on 27 April 2018. Effective 21 May 2021, Sector Sigma Nordic Fund's authorisation was revoked by the Central Bank of Ireland.

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

SCHEDULE OF INVESTMENTS

As at 30 June 2021

Sector Healthcare Value Fund

Sector Healthcare value Fund		Fair Value as a % of	
Investment	Units/Contracts	Net Assets	Fair Value USD
<u>Financial Assets at Fair Value through profit or loss</u> Equities			
<u>Belgium</u>			
UCB S.A.	137,450	2.98%	14,370,252
Total Belgium		2.98%	14,370,252
<u>Canada</u>			
Aurinia Pharmaceuticals, Inc.	135,480	0.36%	1,755,821
Total Canada		0.36%	1,755,821
Denmark	120.025	0.020	4 402 125
H Lundbeck A/S Total Denmark	139,025	0.92%	4,423,135 4,423,135
Total Delimark		0.92%	4,423,133
France BioMerieux	29.096	0.020	4 426 286
Ipsen S.A.	38,086 46,230	0.92% 1.00%	4,426,286 4,809,175
Sanofi	143,343	3.11%	15,020,358
Total France		5.03%	24,255,819
Germany			
Evonik Industries AG	115,686	0.80%	3,879,790
Total Germany		0.80%	3,879,790
Ireland			
Medtronic Plc	118,289	3.04%	14,683,213
Perrigo Co. Plc	111,501	1.06%	5,112,321
Total Ireland		4.10%	19,795,534
<u>Japan</u>			
Astellas Pharma, Inc.	239,100	0.86%	4,167,393
Eisai Co. Ltd. Miraca Holdings, Inc.	61,467 78,912	1.25% 0.42%	6,050,338 2,036,255
Otsuka Holdings Co. Ltd.	150,832	1.30%	6,260,771
Santen Pharmaceutical Co. Ltd.	308,266	0.88%	4,249,455
Shimadzu Corp.	89,195	0.72%	3,451,595
Total Japan		5.43%	26,215,807
Netherlands			
Koninklijke Philips NV	252,147	2.59%	12,496,093
Qiagen NV Total Netherlands	94,168	0.94% 3.53%	4,555,848
Total Netherlands		3.33%	17,051,941
Sweden Biovitrum AB	02.211	0.250	1,682,562
Total Sweden	92,211	0.35%	1,682,562
		0.33 //	1,002,302
United Kingdom ConvaTec Group Plc	519,081	0.36%	1,725,305
GlaxoSmithKline Plc	1,836,821	7.46%	36,016,940
LivaNova Plc	14,803	0.26%	1,245,080
Smith & Nephew Plc	598,067	2.67%	12,909,370
Total United Kingdom		10.75%	51,896,695
<u>United States</u>			
Alnylam Pharmaceuticals, Inc.	37,949	1.33%	6,433,115
Anthem, Inc. Baxter International, Inc.	24,756 101,624	1.96% 1.69%	9,451,841 8,180,732
Becton Dickinson & Co.	52,507	2.65%	12,769,177
Biogen, Inc.	40,485	2.90%	14,018,741
BioMarin Pharmaceutical, Inc.	37,420	0.65%	3,122,325
Bio-Rad Laboratories, Inc. Boston Scientific Corp.	7,806 240,974	1.04% 2.13%	5,029,328 10,304,048
Bristol-Myers Squibb Co.	328,557	4.55%	10,304,048 21,954,179
···	220,337	1.55 /0	=1,751,177

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

SCHEDULE OF INVESTMENTS (Continued)

As at 30 June 2021

Sector Healthcare Value Fund (Continued)

Sector meaniteare varue runa (continuea)	Fai	r Value as a % of	
Investment	Units/Contracts	Net Assets	Fair Value USD
Financial Assets at Fair Value through profit or loss			
(continued)			
Equities (continued)			
II. to 1 Character (continued)			
United States (continued)	166,018	2.6107	12 614 049
Bruker Corp. Cardinal Health, Inc.		2.61% 2.13%	12,614,048
	179,766	1.98%	10,262,841
Centene Corp.	130,899	1.92%	9,546,464
CVS Health Corp. Elanco Animal Health, Inc.	111,200 216,512	1.56%	9,278,528 7,510,801
Gilead Sciences, Inc.	332,010	4.74%	22,862,209
Henry Schein, Inc.	102,681	1.58%	7,617,903
Hologic, Inc.	72,970	1.01%	4,868,558
Incyte Corp. Ltd.	152,787	2.66%	12,853,970
Ionis Pharmaceuticals, Inc.	136,798	1.13%	5,456,872
Johnson & Johnson	30,000	1.02%	4,942,200
Laboratory Corporations of America Holdings	26,014	1.49%	7,175,962
Merck & Co., Inc.	311,796	5.02%	24,248,375
Novavax, Inc.	6,699	0.29%	1,422,265
NuVasive, Inc.	145,148	2.04%	9,838,131
Organon & Co.	309,009	1.94%	9,350,612
Patterson Cos., Inc.	69,838	0.44%	2,122,377
PerkinElmer, Inc.	43,483	1.39%	6,714,210
Pfizer, Inc.	724,726	5.88%	28,380,270
Regeneron Pharmaceuticals, Inc.	4,876	0.56%	2,723,441
Rigel Pharmaceuticals, Inc.	846,651	0.76%	3,674,465
Sage Therapeutics, Inc.	53,129	0.63%	3,018,259
Universal Health Services, Inc.	15,957	0.48%	2,336,584
Total United States	13,557	62.17%	300,082,831
Total Office States		02.1770	300,062,631
Total Equities		96.42%	465,410,187
Money Market Funds			
Goldman Sachs US\$ Treasury Liquid Reserves Fund	20,000,000	4.14%	20,000,000
Total Money Market Funds		4.14%	20,000,000
Total House Hamilton I talked			20,000,000
Net unrealised gain on forward foreign currency contracts (Note 7)		0.24%	1,158,129
			<u> </u>
Total Financial Assets at Fair Value through profit or loss		100.84%	486,568,316
Financial Liabilities at Fair Value through profit or loss			
Net unrealised loss on forward foreign currency contracts (Note 7)		(1.39)%	(6,726,131)
Total Financial Liabilities at Fair Value through profit or loss		(1.43)%	(6,726,131)
Total Investments at Fair Value		99.41%	479,842,185
Cash at bank and brokers		1.64%	7,910,703
Liabilities in excess of other assets		(1.05)%	(5,058,418)
Total Net Assets		100.00%	482,694,470
ATT GEOTIDIANS ADE IDANGEEDADTE GEOTIDIANS ADMIN		NOTE A NOTE A FORM	NIC OD TO ADED

ALL SECURITIES ARE TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL EXCHANGE LISTING OR TRADED ON A REGULATED MARKET EXCEPT FOR FORWARD FOREIGN CURRENCY CONTRACTS AND CONTRACTS-FOR-DIFFERENCE WHICH ARE FINANCIAL DERIVATIVE INSTRUMENTS

Analysis of Total Assets	% of Total Assets
Transferable securities admitted to an official exchange listing or traded on a regulated market	100.56%
Financial derivative instruments	(1.15)%
Other assets	0.59%
Total Assets	100.00%

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS

1. Organisation and Structure

Sector Capital Funds plc (the "Company") was incorporated and registered in Ireland with registered number 489443 and is governed by the Companies Acts 2014 as an open-ended umbrella investment company with variable capital and with segregated liability between sub-funds on 27 September 2010. The Company is authorised by the Central Bank of Ireland pursuant to European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48 (1) (Undertakings for Collective Investment in Transferable Securities) Regulations, 2019 (the "Regulations").

As at 30 June 2021, the Company has two funds in existence (30 June 2020: three), Sector Healthcare Value Fund and Harvest Equity Kernel (formerly Sector Global Equity Kernel). Harvest Equity Kernel ceased trading effective 15 January 2021. Effective 21 May 2021, Sector Sigma Nordic Fund's authorisation was revoked by the Central Bank of Ireland. An application will be made to the Central Bank of Ireland to Harvest Equity Kernel's authorisation revoked.

Sector Healthcare Value Fund commenced trading on 17 November 2010. The base currency of Sector Healthcare Value Fund is United States Dollars ("USD"). As at 30 June 2021, fourteen classes are subscribed to in the Fund (30 June 2021: nine), Class A EUR Shares, Class A NOK Shares, Class A USD Shares, Class B EUR Shares, Class B NOK Shares, Class B SEK Shares, Class B USD Shares, Class X USD Shares, Class X EUR Shares, Class Y GBP Shares, Class Y USD Shares, Class E NOK and Class E USD.

Harvest Equity Kernel commenced trading on 19 March 2014. The base currency of Harvest Equity Kernel was USD. Effective 2 January 2020, the Fund changed its name from Sector Global Equity Kernel to Harvest Equity Kernel. As at 30 June 2021, all share classes have been redeemed and as at 15 January 2021, the Fund ceased operations.

Investment Objective

The investment objective of Sector Healthcare Value Fund is to achieve attractive long term investment returns relative to the MSCI Daily TR World Net Health Care USD (the "Index"). The Index is a capitalisation weighted index that monitors the performance of health care stocks from around the world. The Fund may invest in equities and financial instruments that are not part of the Index. There can be no guarantee that the investment objective of the Fund will be achieved.

The investment objective of Harvest Equity Kernel was to maximise long-term total return relative to MSCI ACWI Index (the "Index"). The Index is a free float-adjusted market capitalisation weighted index that is designed to measure the equity market performance of developed and emerging markets. The MSCI ACWI consists of 45 country indices comprising 24 developed and 21 emerging market country indices. There can be no guarantee that the investment objective of the Fund will be achieved.

The investment objective of Sector Sigma Nordic Fund was to generate attractive risk adjusted return for its investors, primarily through investment in Norway, Sweden, Denmark, Finland and Iceland (the "Nordic Region") with the aim of generating positive returns over time in rising as well as falling equity markets.

2. Summary of Significant Accounting Policies

The financial statements have been prepared in accordance with Financial Reporting Standard 102 ("FRS 102"), the Financial Reporting Standard applicable in the UK and Republic of Ireland, the Companies Acts 2014, the Regulations.

The financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets and financial liabilities at fair value through profit or loss in accordance with the European Communities (Fair Value Accounting) Regulations 2011.

The Company has availed of certain exemptions available to open-ended investment funds in FRS 102 not to prepare a cash flow statement in paragraph 7.1A of FRS 102.

The preparation of financial statements in accordance with FRS 102 requires Directors to make judgements, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the financial period. Actual results could differ from those estimates.

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

2. Summary of Significant Accounting Policies (Continued)

The financial statements of the Company have been prepared on a going concern basis. The Company is able to meet all of its liabilities from its assets. The performance, marketability and risks of the Company are reviewed on a regular basis throughout the financial period. Therefore, the Directors believe that the Company will continue in operational existence for the foreseeable future and is financially sound. The Directors are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements of the Company.

(a) Portfolio valuation

Investment transactions

(i) Classification

The Company classifies all of its investments as financial assets or financial liabilities at fair value through profit or loss. These financial instruments are designated on the basis that their fair value can be reliably measured and their performance has been evaluated on a fair value basis in accordance with the risk management and/or investment strategy as set out in the Company's Prospectus.

(ii) Recognition

The Company recognises financial assets and financial liabilities on the date it becomes party to the contractual provisions of the instrument. Investment transactions are accounted for on a trade date basis at cost. Purchases and sales of securities are accounted for on the trade date on which the transaction takes place. Transaction costs are expensed immediately to the Profit and Loss Account and not capitalised as part of cost of the investment.

(iii) Measurement

Financial assets and financial liabilities held for trading are measured at fair value. Fair value is the amount for which an asset could be exchanged, or a liability settled, between knowledgeable, willing parties in an arms length transaction.

Realised gains and losses on sales of investments are calculated on a First-In, First-Out ("FIFO") basis. Unrealised gains and losses on investments are recognised in the Profit and Loss Account. Forward foreign currency contracts and any other instruments held by the Company and traded on an exchange will be measured at fair value based on the last reported traded price on such regulated market as at the relevant valuation point.

If an investment is quoted, listed or normally dealt in on more than one market, the Directors may, in their absolute discretion, select any of such markets for the valuation purposes.

(iv) Derecognition

The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire or it transfers the financial asset and the transfer qualifies for derecognition.

A financial liability is derecognised when the obligation specified in the contract is discharged, cancelled or expired.

(b) Forward foreign currency contracts

The unrealised gain or loss on open forward foreign currency contracts is calculated by reference to the difference between the contracted rate and the rate to close out the contract. Realised gains or losses include net gains on contracts which have been settled or offset by other contracts.

(c) Options

When the Company writes or purchases put or call options, an amount equal to the premium received or paid is recorded as a liability or an asset and is subsequently marked-to-market based on quoted market prices in the Balance Sheet. Premiums received or paid from writing or purchasing put or call options which are expired or were unexercised are recognised on the expiration date as realised gains or losses in the Profit and Loss Account. If an option is exercised, the premium received or paid is included with the proceeds or the cost of the transaction to determine whether the Company has realised a gain or loss on the related investment transaction in the Profit and Loss Account. When the Company enters into a closing transaction, the Company will realise a gain or loss in the Profit or Loss Account depending upon whether the amount from the closing transaction is greater or less than the premium received or paid.

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

2. Summary of Significant Accounting Policies (Continued)

(d) Contracts-for-difference

A contract-for-difference ("CFD") is a contract between two parties, buyer and seller, stipulating that the seller will pay to the buyer the difference between the current value of an asset (a security, instrument, basket or index) and its value at contract time. The payment flows are usually netted against each other, with the differences being paid by one party to the other. The unrealised gain or loss depends upon the prices at which the underlying financial instruments of the CFD is valued at and is included in the Profit and Loss Account.

(e) Foreign exchange translation

Items included in the Company's financial statements are measured using the currency of the primary economic environment in which it operates (the "functional currency"). The functional currency of Harvest Equity Kernel was the United States Dollar ("USD"), due to the fact that the majority of the Fund's assets were denominated in USD. The functional currency of Sector Healthcare Value Fund is the United States Dollar ("USD"), due to the fact that the majority of the Fund's assets are denominated in USD and that a substantial portion of capital is issued in USD. The functional currency of Sector Sigma Nordic Fund was Norwegian Krone ("NOK"), due to the fact that the majority of the Fund's assets were denominated in NOK and that a substantial portion of capital was issued in NOK. Each Fund has adopted its functional currency as the presentation currency for these financial statements. Assets and liabilities expressed in foreign currencies are converted into the functional currency of each Fund using the exchange rates prevailing as at the balance sheet date. Transactions in foreign currencies are translated into the Fund's functional currency at exchange rates ruling at the transaction dates. Gains and losses on foreign exchange transactions are recognised in the Profit and Loss Account in determining the result for the period.

At 30 June 2020, in accordance with FRS 102, a period end exchange rate of NOK/USD 0.1032 was used to translate the Balance Sheet of Sector Sigma Nordic Fund in arriving at the total USD value for the Company in the financial statements.

(g) Offsetting financial instruments

Financial assets and financial liabilities may be offset and the net amount reported in the Balance Sheet when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously. As at 30 June 2021 and 30 June 2020, no offsetting has been presented in the Balance Sheet.

(h) Income

Dividends are recognised as income on the dates that securities are first quoted "ex-dividend" to the extent information thereon is reasonably available to the Company. Interest income is accrued on a daily basis. Deposit interest is recognised as income on an accruals basis.

(i) Expenses

Operating expenses are accounted for on an accruals basis.

(j) Net asset value per share

The Net Asset Value per Share of each class is calculated by dividing the Net Asset Value attributable to a class by the number of shares of a class in issue as at the relevant valuation point.

(k) Redeemable participating shares

Shares issued by each Fund provide shareholders with the right to redeem their shares, for cash equal to their proportional share of the net asset value of the Fund and are classified as financial liabilities in accordance with FRS 102. The Fund does not meet the requirement to be classified as equity as the Fund offers different classes of shares with varying rights attached to them. The liabilities to shareholders are presented on the Balance Sheet as "Net assets attributable to holders of Redeemable Participating Shares" and are determined based on the residual assets of the Fund after deducting the Fund's other liabilities.

(l) Amounts due from/to broker

Amounts due from/to broker relate to the outstanding amounts pending settlement on forward foreign currency contracts and upfront cash payments for fully funded contracts-for-difference.

(m) Taxation

The Company incurs dividend withholding tax and other taxation imposed by certain countries on investment income and gains on investments. Dividend income is shown gross of any non-recoverable withholding taxes, which are disclosed separately in Profit and Loss Account.

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

2. Summary of Significant Accounting Policies (Continued)

(n) Transaction costs

Transaction costs are costs incurred to acquire financial assets or financial liabilities at fair value through profit or loss. They include fees and commissions paid to agents, advisers, brokers and dealers. Transaction costs, when incurred, are immediately recognised in profit or loss as an expense. For the financial period ended 30 June 2021 Harvest Equity Kernel incurred transaction costs of USD86,854 (30 June 2020: USD62,919), Sector Healthcare Value Fund incurred transaction costs of USD201,363 (30 June 2020: USD93,100).

(o) Cash

Cash at bank and brokers represents, cash and cash equivalents, with original maturities of three months or less held with the Depositary and brokers.

3. Dividend and Distribution Policy

The Directors do not currently intend to pay dividends. Accordingly, the price of the shares shall rise as income and capital gains accrue.

4. Taxation

The Company will not be liable to tax in respect of its income and gains, other than on the occurrence of a chargeable event. Generally a chargeable event arises on any distribution, redemption, repurchase, cancellation, transfer of shares or on the ending of a 'Relevant Year', a 'Relevant Year' being an eight year period beginning with the acquisition of the shares by the shareholders and each subsequent year of eight years beginning immediately after the preceding relevant year.

A chargeable event does not include:

- (i) Any transactions in relation to shares held in a recognised clearing system: or
- (ii) An exchange of shares representing a fund for another fund: or
- (iii) An exchange of shares arising on a qualifying amalgamation or reconstruction of a Fund with another fund: or
- (iv) Certain exchanges of shares between spouses and former spouses.

A chargeable event will not occur in respect of shareholders who are neither resident nor ordinarily resident in Ireland and who have provided the Company with a relevant declaration to that effect.

In the absence of an appropriate declaration, the Company will be liable to Irish Tax on the occurrence of a chargeable event. There were no chargeable events during the period under review. Capital gains, dividends and interest received may be subject to withholding taxes imposed by the country of origin and such taxes may not be recoverable by the Company or its shareholders.

5. Exchange Rates

The following exchange rates (against USD) were used to convert the investments and other assets and liabilities denominated in currencies other than USD as at 30 June 2021 and 30 June 2020:

Currency	30 June 2021	30 June 2020
Australian Dollar	-	1.4524
Brazilian Real	-	5.4908
British Pound	0.7239	0.8093
Canadian Dollar	-	1.3620
Danish Krone	6.2696	6.6360
Euro	0.8432	0.8904
Hong Kong Dollar	-	7.7504
Hungarian Forint	294.1176	-
Japanese Yen	111.1111	107.8865
Korean Won	-	1,203.3694
Norwegian Krone	8.6059	9.6470
Singapore Dollar	-	1.3952
Swedish Krona	8.5521	9.3166
Swiss Franc	0.9244	0.9476
Taiwan Dollar	-	29.5046
Thailand Baht	-	0.0324

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

5. Exchange Rates (Continued)

The following exchange rates (against NOK) were used to convert the investments and other assets and liabilities denominated in currencies other than NOK as at 30 June 2020.

Currency	30 June 2020
Australian Dollar	0.1506
British Pound	0.0839
Canadian Dollar	0.1412
Danish Krone	0.6879
Euro	0.0923
Hong Kong Dollar	0.8034
Japanese Yen	11.1834
Swiss Franc	0.9658
US Dollar	0.0982

6. Cash

As at 30 June 2021, all cash balances (including overdrafts) are held with The Bank of New York Mellon SA/NV, Dublin Branch (the "Depositary"). As at 30 June 2020, all cash balances (including overdrafts) were held with The Bank of New York Mellon SA/NV, Dublin Branch (the "Depositary"), DNB and Goldman Sachs.

30 June 2021	Harvest Equity Kernel	Sector Healthcare Value Fund	Sector Sigma Nordic Fund
	USD	USD	NOK
BNY Mellon	12,869	7,910,703	-
	12,869	7,910,703	-
30 June 2020	Harvest Equity Kernel	Sector Healthcare Value Fund	Sector Sigma Nordic Fund
	USD	USD	NOK
BNY Mellon	8,132,415	(261,671)	899,643
DNB	6,125,701	-	-
Goldman Sachs	1,910,127	-	-
	16,168,243	(261,671)	899,643

As at 30 June 2021, there was no collateral pledged. As at 30 June 2020, Harvest Equity Kernel pledged USD1,910,127 as collateral with Goldman Sachs.

7. Financial Instruments and Associated Risks

Included in the Company's financial instruments, but not limited to, are global equities and equity related securities (including but not limited to American Depositary Receipts, Global Depositary Receipts, European Depositary Receipts and other equity based derivatives), corporate bonds and government debt obligations that shall be listed or traded on any market.

The main risks arising from the Company's financial instruments are market price, liquidity, interest rate, foreign currency and credit risks.

The Market Risk Group ("MRG") functions across all Sector Investment Manager entities and the group is responsible for defining risk management related limits ("soft limits") in addition to the investment restrictions found in the Prospectus and related supplements, in cooperation with the respective Investment Manager, securing that the Funds have a portfolio construction and risk exposure that are in line with the intentions of the individual Funds. The limits are generally related to exposure towards single positions and sectors, total portfolio exposure and Value-at-Risk ("VAR"). MRG consists of the CEO of Sector Asset Management AS (leader of MRG), Head of Fund Operations, the CCO and CEO of Sector Fund Services AS. The Head of Fund Operations has the mandate to give short term exceptions to the risk limits set by MRG if he/she finds that under certain market conditions, the limits have unintended adverse effects, for example in extreme market conditions. Such exceptions are reported to the other members of MRG and to the Group Chief Compliance Officer.

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(a) Market price risk

Market price risk arises from uncertainty concerning future prices of financial instruments. The consequence might be a decline in the Fund's value. The risk related to the Funds – i.e. a combination of the probability of loss and the consequences – must be weighed against the potential gain for the Fund. To limit the risk, the Funds are both diversified and constructed through fundamental analyses of the expected behaviour and volatility of the individual instruments while following each Fund's investment objective.

Value-at-Risk

Value-at-Risk (VaR) represents the potential loss one might suffer given a defined confidence interval and time horizon. The measure is one of the main risk measures for the Company under normal market conditions.

One of the key metrics used by the Sector Group to measure market risk is VAR which encompasses currency, interest rate and price risk.

The main risk management tool for VaR calculations was Bloomberg. For all Funds, the Bloomberg VaR calculation is based on Monte Carlo simulations at a 95% confidence interval i.e. that one in every 20 days is expected to be above this measure in the long run.

For the financial period ended 30 June 2021

For the financial period ended 30 June 2021	Period end VaR	Gross Exposure*	Net Exposure**	lowest VaR	highest VaR	average VaR
Sector Healthcare Value Fund	1.84%	96.4%	96.4%	1.79%	2.29%	2.04%
For the financial period ended 30 June 2020	Period end VaR	Gross Exposure*	Net Exposure**	lowest VaR	highest VaR	average VaR
		- ···· • • · · · · · · · · · · · · · · ·	I		8	8
Harvest Equity Kernel	2.08%	89.3%	89.3%	0.81%	2.32%	1.63%
Harvest Equity Kernel Sector Healthcare Value Fund	2.08% 2.74%	89.3% 93.7%	89.3% 93.7%	0.81% 1.16%	2.32% 2.81%	1.63% 2.10%

Exposure

Exposure for pure equities is equal to the fair value of the securities. The total gross exposure of each Fund is the sum of the absolute values of all long and short exposures.

(b) Interest rate risk

Interest rate risk is the risk (variability in value) borne by an interest-bearing asset, due to variability of interest rates. In general, as rates rise, the price of a fixed rate bond will fall, and vice versa. Interest rate risk is commonly measured by the bond's duration. For the financial period ended 30 June 2021 and 30 June 2020 the Funds, have not invested in interest bearing assets, other than cash amounts. As at 30 June 2021 and 30 June 2020, the Funds do not have any significant fair value interest rate risk exposure.

Tables outlining the currency and interest exposure as at 30 June 2021 and 30 June 2020 are outlined in note 7(d).

(c) Liquidity risk

Liquidity risk is linked to the Funds having to realise assets in unfavourable market conditions with large losses as a consequence due to for example, redemptions in a Fund or a collapse in long asset values reducing the collateral held by counterparties leading to margin calls, if applicable. This means that there are two aspects that are monitored; what is the probability of the situation occurring and how fast can the Funds realise their positions without significant adverse effects on the value of the positions.

Liquidity of portfolio

The Company's Prospectus provides for daily subscription and redemption of shares in the Funds, therefore the Funds are exposed to a liquidity risk of meeting shareholder redemptions on a daily basis. The majority of the Funds' assets are comprised of publicly traded securities and are thus relatively easily realised. Still, with each Fund having the possibility to take positions in small cap equities, the ability of a Fund to realise assets within a short period of time without a large negative impact on the value of the assets is important. Some of the recognised exchanges on which a Fund may invest may prove to be less liquid or highly volatile from time to time. The Funds may invest a limited proportion of their assets in unquoted securities.

For the financial period ended 30 June 2021 and 30 June 2020, the Funds held very liquid assets and liquidity was monitored daily by the Investment Managers.

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(c) Liquidity risk (Continued)

The reports below are snapshots of the estimated liquidity of the Funds as at 30 June 2021 and 30 June 2020:

Sector Healthcare Value Fund

Description	Cumulative
< 1 day	98.0%
1-2 day s	100%
3-5 days	100%

Harvest Equity Kernel		Sector Healthcare Value Fund	l
Description	Cumulative	Description	Cumulative
< 1 day	100%	< 1 day	99%
1-2 day s	100%	1-2 days	100%
3-5 days	100%	3-5 days	100%

(d) Foreign currency risk

Foreign currency risk is in reality a sub-group of market risk, but with its own idiosyncrasies, both with respect to a Fund's portfolio as well as the investor classes denominated in different currencies. Certain currency related transactions may, for example, be employed by the Funds in order to hedge against foreign exchange risk subject to the conditions and limits laid down by the Central Bank of Ireland. Such transactions include forward foreign currency contracts and may for example be executed in cases where an investment is in a currency other than the Fund's functional currency.

A substantial portion of the financial assets of the Funds are denominated in currencies other than the relevant Fund's functional currency with the effect that the balance sheet of the Funds can be significantly affected by currency movements.

Currency exposure for investor classes

The shares of the Company are denominated in United States Dollar (USD), Euro (EUR), Norwegian Krone (NOK), British Pound (GBP) and Swedish Krona (SEK) and are issued and redeemed in those currencies. The Investment Manager may seek to hedge the foreign currency exposure of the assets attributable to the shares in order to neutralise as far as reasonably possible, the impact of fluctuations in exchange rates. This is done monthly in addition to when a Fund has more than 3% absolute return, month to date. There is no guarantee that such hedging will give returns that are equal regardless of which currency the shareholders have invested in. In addition, shareholders whose assets and liabilities are predominantly in currencies other than the currency of investment in the Company should take into account the potential risk of loss arising from fluctuations in value between USD, EUR, NOK, GBP or SEK being the currency of shareholder investment, and such other currencies as invested in by the Company.

Portfolio currency exposure

The Funds trade in many different markets across the world and in many different currencies. Thus, certain assets in the portfolio may, regardless of the shares of the Fund, be invested in securities which are denominated in currencies other than USD, EUR, NOK, GBP or SEK. Consequently, the value of such assets will be affected either favourably or unfavourably by fluctuations in currency rates. The exposure towards the different currencies based on the denomination of the securities is reported daily for each Fund. For each individual Fund, action towards currency exposure in the portfolio is taken by the Investment Manager based on reported exposure of the Fund's assets.

Amounts represented below primarily are monetary assets and monetary liabilities except for investments in non-interest bearing securities, which include equities and contracts-for-difference, which are non-monetary assets.

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(d) Foreign currency risk (Continued)

The foreign currency exposure as at 30 June 2021 is as follows:

Harvest Equity Kernel	Cash at Bank and Brokers	Forward Currency Contracts	Investments in Interest Bearing Assets	Investments in Non-Interest Bearing Assets	Investments in Non-Interest Bearing Liabilities	Net Other Assets/ (Liabilities)	Total Net Asset Value
Currency	USD	USD	USD	USD	USD	USD	USD
BRL	_		_		_	4,539	4,539
EUR	1,200	_	_	_	_	_	1,200
USD	11,669	_	-	-	-	(17,408)	(5,739)
Total	12,869	-	-	-	-	(12,869)	_
Sector Healthcare	Cash at Bank and Brokers	Forward Currency Contracts	Investments in Interest Bearing Assets	Investments in Non-Interest Bearing Assets	Investments in Non-Interest Bearing Liabilities	Net Other Assets/ (Liabilities)	Total Net Asset Value
Value Fund	USD	USD	LICD	LICD	LICD	LICD	USD
Currency		USD	USD	USD	USD	USD	
CHF	274	_	_	4 402 125	_	_	274
DKK EUR	140 192,550	(1,502,483)	_	4,423,135	_	- (4)	4,423,275
GBP	36,671	(1,302,463)	_	55,001,954 50,651,615	_	(4) 463,235	53,692,017 51,151,521
JРY	32,713	_	_	26,215,807	_	57,542	26,306,062
NOK	(280,457)	(3,946,611)	_	20,213,607	_	31,342	(4,227,068)
SEK	388,672	(118,908)	_	1,682,562	_	(688,350)	1,263,976
USD	7,540,140	(110,500)	_	347,435,114	_	(4,890,841)	350,084,413
Total	7,910,703	(5,568,002)		485,410,187		(5,058,418)	482,694,470

The foreign currency exposure as at 30 June 2020 is as follows:

	Cash at Bank	Forward Currency	Investments in Interest	Investments in Non-Interest	Investments in Non-Interest	Net Other Assets/	Total Net
Harvest	and Brokers	Contracts	Bearing Assets	Bearing Assets	Bearing Liabilities	(Liabilities)	Asset Value
Equity Kernel			8	g	- ····- 8 ···	(======)	
Currency	USD	USD	USD	USD	USD	USD	USD
AUD	415	(49,826)	_	7,317,350	_	8,645	7,276,584
BRL	52	_	_	_	_	68,092	68,144
CAD	7,141	114,931	_	9,076,341	_	_	9,198,413
CHF	840	_	_	7,458,463	_	_	7,459,303
CNY	_	(59,448)	_	275,280	(96,121)	-	119,711
DKK	124	_	_	_	_	-	124
EUR	1,347	10,739	_	6,079,465	_	953	6,092,504
GBP	12,463	_	_	1,202,532	_	13,961	1,228,956
HKD	50,636	(5,207)	_	7,180,931	_	-	7,226,360
INR	_	(8,255)	_	13,790	_	_	5,535
JPY	55,217	96,860	_	11,658,953	_	-	11,811,030
KRW	_	(46,870)	_	2,483,468	_	7,461	2,444,059
NOK	286,761	1,130,040	_	_	_	61,576	1,478,377
SEK	11,850	_	_	1,122,468	_	20,476	1,154,794
SGD	421	_	_	_	_	_	421
THB	27	_	_	_	_	_	27
TRY	2	_	_	_	_	_	2
TWD	_	(47,173)	_	4,301,025	_	9,505	4,263,357
USD	15,894,357		_	56,735,584	-	(562,201)	72,067,741
Total	16,321,654	1,135,791	-	114,905,650	(96,121)	(371,532)	131,895,442

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(d) Foreign currency risk (Continued)

	Cash at Bank	Forward Currency	Investments in Interest	Investments in Non-Interest	Investments in Non-Interest	Net Other Assets/	Total Net
Sector	and Brokers	Contracts	Bearing Assets	Bearing Assets	Bearing Liabilities	(Liabilities)	Asset Value
Healthcare							
Value Fund							
Currency	USD	USD	USD	USD	USD	USD	USD
CHF	541	_	-	2,174,802	_	_	2,175,343
DKK	253	_	_	_	_	_	253
EUR	31,559	478,533	_	34,702,120	_	(100,735)	35,111,477
GBP	3,575	_	-	17,333,071	_	125,281	17,461,927
HUF	12	-	-	1,901,270	_	-	1,901,282
JPY	5	-	-	11,106,585	_	34,944	11,141,534
NOK	149,718	2,085,047	-	_	_	(62,994)	2,171,771
SEK	8,280	60,738	-	_	_	(531,234)	(462,216)
USD	(455,049)		_	142,911,070	_	(3,053,306)	139,402,715
Total	(261,106)	2,624,318	_	210,128,918	_	(3,588,044)	208,904,086
,	· · ·						

Sector Sigma Nordic Fund	Cash at Bank and Brokers	Forward Currency Contracts	Investments in Interest Bearing Assets	Investments in Non-Interest Bearing Assets	Investments in Non- Interest Bearing Liabilities	Net-Other Assets/ (Liaibilties)	Total Net Asset Value
Currency	NOK	NOK	NO K	NOK	NO K	NOK	NO K
EUR	_	_	_	_	_	(12,460)	(12,460)
NOK	_	_	_	_	_	486	486
USD	889,643	_	_	_	_	(887,669)	(887,669)
Total	899,643	-	-	-	-	(899,643)	

As at 30 June 2021 the following forward foreign currency contracts were held by the Funds:

Sector Healthcare Value Fund

				Purchase		Unrealised
Maturity Date	Counterparty	Sale Currency	Amount	Currency	Amount	gain/(loss) USD
01 July 2021	BNY Mellon	EUR	(79,625)	USD	96,944	2,515
01 July 2021	BNY Mellon	EUR	(8,726,419)	USD	10,396,045	47,167
01 July 2021	BNY Mellon	EUR	(110,651)	USD	131,822	598
01 July 2021	BNY Mellon	EUR	(35,043,862)	USD	41,748,804	189,412
01 July 2021	BNY Mellon	NOK	(682,479)	USD	82,381	3,070
01 July 2021	BNY Mellon	NOK	(6,482)	USD	781	28
01 July 2021	BNY Mellon	NOK	(151,886)	USD	18,286	635
01 July 2021	BNY Mellon	NOK	(731,336)	USD	87,651	2,663
01 July 2021	BNY Mellon	NOK	(325,059)	USD	38,997	1,222
01 July 2021	BNY Mellon	NOK	(240,837)	USD	28,714	726
01 July 2021	BNY Mellon	NOK	(1,502,003)	USD	176,728	2,181
01 July 2021	BNY Mellon	NOK	(237,014,987)	USD	27,730,781	187,404
01 July 2021	BNY Mellon		(857,148,990)	USD	100,286,532	677,736
01 July 2021	BNY Mellon		(33,708,018)	USD	3,943,842	26,652
01 July 2021	BNY Mellon		(1,730,407)	USD	201,316	226
01 July 2021	BNY Mellon		(89,013)	USD	10,226	(118)
01 July 2021	BNY Mellon		(67,824)	USD	8,220	289
01 July 2021	BNY Mellon		(22,224)	USD	2,690	91
01 July 2021	BNY Mellon		(8,951)	USD	1,074	27
01 July 2021	BNY Mellon		(29,337)	USD	3,522	92
01 July 2021	BNY Mellon		(34,339,894)	USD	4,029,856	14,464
01 July 2021	BNY Mellon		(7,371,755)	EUR	6,042,016	(206,377)
01 July 2021	BNY Mellon		(129,456)	EUR	106,104	(3,625)
01 July 2021	BNY Mellon		(40,915,566)	EUR	33,535,095	(1,145,459)
01 July 2021	BNY Mellon		(3,053,718)	EUR	2,500,000	(88,905)
01 July 2021	BNY Mellon		(321,959)	EUR	264,028	(8,842)
01 July 2021	BNY Mellon		(5,545)	EUR	4,547	(153)
01 July 2021	BNY Mellon	USD	(1,839,810)	EUR	1,508,767	(50,525)

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(d) Foreign currency risk (Continued)

Sector Healthcare Value Fund (continued)

Natural Date	Sector Healthcare value Fund (continued)				Purchase		Unrealised
01 July 2021 BRY Mellon USD (27,122,963) NOK 226,707,831 (777,375)	Maturity Data	Counterparty	Sale Currency	Amount		Amount	
1 July 2021 BNY Mellon USD (97,484,295) NOK 814,824,428 (2,794,012)	•						0 \
1 July 2021 BNY Mellon USD (3.566,340) NOK 29,809,324 (102,215)	•						
1 11 2021 BNY Mellon USD (125,047) NOK 3,044,718 (106,50) 1 11 2021 BNY Mellon USD (66,1475) NOK 3,044,718 (106,50) 1 11 2021 BNY Mellon USD (60,196) NOK 500,000 (2,091) 1 11 2021 BNY Mellon USD (179,988) NOK 149,254 (613) 1 11 12 2021 BNY Mellon USD (179,988) NOK 2,500,000 (13,015) 1 11 12 2021 BNY Mellon USD (318,192) NOK 2,500,000 (13,015) 1 11 12 2021 BNY Mellon USD (318,192) NOK 2,500,000 (116,73) 1 11 12 2021 BNY Mellon USD (43,588) NOK 36,055 (168) 1 11 12 2021 BNY Mellon USD (43,588) NOK 9,807,156 (47,993) 1 11 12 2021 BNY Mellon USD (43,27,195) NOK 9,807,156 (47,993) 1 11 12 2021 BNY Mellon USD (169,386) NOK 1,108,844 (46,30) 1 11 12 2021 BNY Mellon USD (169,386) NOK 1,108,844 (46,30) 1 11 12 2021 BNY Mellon USD (28,615) NOK 239,834 (742) 1 11 12 2021 BNY Mellon USD (24,463) NOK 384,377 (59) 1 1 11 12 2021 BNY Mellon USD (44,472) NOK 384,377 (59) 1 1 11 12 2021 BNY Mellon USD (44,472) NOK 384,377 (59) 1 1 1 1 1 1 1 1 1	•						
1 11 2021 BNY Mellon USD (364,475) NOK 3,044,718 (10,650) 1 11 2021 BNY Mellon USD (17,958) NOK 4,026,607 (13,015) 1 11 2021 BNY Mellon USD (17,958) NOK 2,026,007 (13,015) 1 11 11 12 12 BNY Mellon USD (31,192) NOK 2,026,007 (13,015) 1 11 12 2021 BNY Mellon USD (30,21,97) NOK 2,00000 (11,673) 1 11 12 2021 BNY Mellon USD (4,358) NOK 36,055 (168) 1 11 12 2021 BNY Mellon USD (4,357) NOK 3,607,156 (47,933) 1 11 12 2021 BNY Mellon USD (4,357,195) NOK 3,573,1486 (174,859) 1 11 12 2021 BNY Mellon USD (4,357,195) NOK 3,573,1486 (174,859) 1 11 12 2021 BNY Mellon USD (133,493) NOK 1,398,694 (6,844) 1 1 1 1 1 1 1 1 1	•						
1 11 2021 BNY Mellon USD (66,196) NOK 500,000 (2,091)	•						
1 1 1 2 2 2 3 3 4 6 3 3 1 2 3 5 1 3 2 3 3 3 3 3 3 3 3	•						
01 July 2021 BNY Mellon USD (318,192) NOK 2,626,097 (13,015) 01 July 2021 BNY Mellon USD (4,328) NOK 36,055 (168) 01 July 2021 BNY Mellon USD (4,328) NOK 36,055 (168) 01 July 2021 BNY Mellon USD (4,327,195) NOK 35,731,486 (174,859) 01 July 2021 BNY Mellon USD (169,386) NOK 1,398,694 (6,844) 01 July 2021 BNY Mellon USD (169,386) NOK 1,398,694 (6,844) 01 July 2021 BNY Mellon USD (28,615) NOK 239,854 (742) 01 July 2021 BNY Mellon USD (23,615) NOK 239,854 (742) 01 July 2021 BNY Mellon USD (44,727) NOK 348,4377 (59) 01 July 2021 BNY Mellon USD (14,4477) NOK 122,762 (181) 01 July 2021 BNY Mellon USD (14,4477) NOK 122,762 (181) 01 July 2021 BNY Mellon USD (14,4477) NOK 122,762 (181) 01 July 2021 BNY Mellon USD (24,643) NOK 207,291 (374) 01 July 2021 BNY Mellon USD (24,643) NOK 207,291 (374) 01 July 2021 BNY Mellon USD (3,849,464) SEK 31,969,779 (111,211) 01 July 2021 BNY Mellon USD (3,643) SEK 113,000 (430) 01 July 2021 BNY Mellon USD (3,643) SEK 113,000 (430) 01 July 2021 BNY Mellon USD (3,643) SEK 113,000 (430) 01 July 2021 BNY Mellon USD (4,295) SEK 31,969,779 (111,211) 01 July 2021 BNY Mellon USD (4,295) SEK 13,500 (144) 01 July 2021 BNY Mellon USD (4,295) SEK 13,500 (444) 01 July 2021 BNY Mellon USD (4,295) SEK 13,667 (56) 01 July 2021 BNY Mellon USD (16,53) SEK 13,667 (56) 01 July 2021 BNY Mellon USD (16,53) SEK 13,667 (56) 01 July 2021 BNY Mellon USD (16,53) SEK 13,667 (56) 01 July 2021 BNY Mellon USD (16,53) SEK 13,667 (56) 01 July 2021 BNY Mellon USD (16,53) SEK 13,667 (56) 01 July 2021 BNY Mellon USD (15,296) SEK 13,667 (56) 01 July 2021 BNY Mellon USD (13,100)	•						
01 July 2021 BNY Mellon USD (302,197) NOK 2,500,000 (11,673) 01 July 2021 BNY Mellon USD (4,358) NOK 5,6055 (168) 01 July 2021 BNY Mellon USD (1,187,677) NOK 9,807,156 (47,993) 01 July 2021 BNY Mellon USD (4,327,195) NOK 3,5731,486 (142,899) 01 July 2021 BNY Mellon USD (160,386) NOK 1,398,694 (6,844) 01 July 2021 BNY Mellon USD (133,493) NOK 1,108,884 (4,630) 01 July 2021 BNY Mellon USD (44,727) NOK 384,377 (59) 01 July 2021 BNY Mellon USD (7,417) NOK 63,176 (75) 01 July 2021 BNY Mellon USD (7,417) NOK 63,176 (75) 01 July 2021 BNY Mellon USD (34,433) NOK 30,27,510 (3,198) 01 July 2021 BNY Mellon USD <td>•</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	•						
OI July 2021 BNY Mellon USD	•						
OI July 2021 BNY Mellon USD (1,187,677) NOK 9,807,156 (47,993)	•						
01 July 2021 BNY Mellon USD (16)38() (4,327,195) NOK (3,731,486) (174,859) 01 July 2021 BNY Mellon USD (16)38() NOK (1,398,694) (6,844) 01 July 2021 BNY Mellon USD (133,493) NOK (1,108,884) (4,630) 01 July 2021 BNY Mellon USD (44,727) NOK (384,377) (59) 01 July 2021 BNY Mellon USD (44,477) NOK (384,377) (59) 01 July 2021 BNY Mellon USD (44,477) NOK (384,377) (59) 01 July 2021 BNY Mellon USD (7,417) NOK (31,76) (75) 01 July 2021 BNY Mellon USD (24,463) NOK (207,291) (374) 01 July 2021 BNY Mellon USD (355,023) NOK (307,510) (31,98) 01 July 2021 BNY Mellon USD (3,849,464) SEK (31,969,779) (11,211) 01 July 2021 BNY Mellon USD (4,295) SEK (31,300) (430) 01 July 2021 BNY Mellon USD (4,295) SEK (31,300) (440) 01 July 2021 BNY Mellon	•						, ,
01 July 2021 BNY Mellon USD (169,386) NOK 1,398,694 (6,844) 01 July 2021 BNY Mellon USD (133,493) NOK 1,108,884 (4,630) 01 July 2021 BNY Mellon USD (28,615) NOK 239,854 (742) 01 July 2021 BNY Mellon USD (14,477) NOK 384,377 (59) 01 July 2021 BNY Mellon USD (7,417) NOK 63,176 (75) 01 July 2021 BNY Mellon USD (24,643) NOK 20,7291 (374) 01 July 2021 BNY Mellon USD (355,023) NOK 3,027,510 (3,198) 01 July 2021 BNY Mellon USD (3849,464) SEK 31,969,779 (111,211) 01 July 2021 BNY Mellon USD (7,408) SEK 61,633 (201) 01 July 2021 BNY Mellon USD (4,295) SEK 61,633 (201) 01 July 2021 BNY Mellon USD <t< td=""><td>•</td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	•						
1 1 1 2 2 2 3 3 3 3 3 3 3	•						` ' '
01 July 2021 BNY Mellon USD (28,615) NOK 239,854 (742) 01 July 2021 BNY Mellon USD (44,727) NOK 384,377 (59) 01 July 2021 BNY Mellon USD (144,727) NOK 384,377 (59) 01 July 2021 BNY Mellon USD (7,417) NOK 63,176 (75) 01 July 2021 BNY Mellon USD (34,63) NOK 207,291 (374) 01 July 2021 BNY Mellon USD (355,023) NOK 30,27,510 (3,198) 01 July 2021 BNY Mellon USD (3,849,464) SEK 31,969,779 (111,211) 01 July 2021 BNY Mellon USD (7,408) SEK 61,633 (201) 01 July 2021 BNY Mellon USD (4,245) SEK 61,633 (201) 01 July 2021 BNY Mellon USD (4,841) SEK 40,000 (164) 01 July 2021 BNY Mellon USD (4,841) <td>•</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	•						
Ol July 2021 BNY Mellon USD (44,727) NOK 384,377 (59)	•						
01 July 2021 BNY Mellon USD (14,447) NOK 122,762 (181) 01 July 2021 BNY Mellon USD (7,417) NOK 63,176 (75) 01 July 2021 BNY Mellon USD (34,463) NOK 207,291 (374) 01 July 2021 BNY Mellon USD (355,023) NOK 30,27,510 (3,198) 01 July 2021 BNY Mellon USD (3,849,464) SEK 31,969,779 (111,211) 01 July 2021 BNY Mellon USD (7,408) SEK 61,633 (201) 01 July 2021 BNY Mellon USD (4,295) SEK 113,500 (440) 01 July 2021 BNY Mellon USD (2,261) SEK 18,719 (72) 01 July 2021 BNY Mellon USD (4,841) SEK 40,000 (164) 01 July 2021 BNY Mellon USD (16,53) SEK 13,657 (56) 01 July 2021 BNY Mellon USD (20,102)	•					,	
01 July 2021 BNY Mellon USD (7,417) NOK 63,176 (75) 01 July 2021 BNY Mellon USD (24,463) NOK 207,291 (374) 01 July 2021 BNY Mellon USD (355,023) NOK 3,027,510 (3,198) 01 July 2021 BNY Mellon USD (3,849,464) SEK 31,969,779 (111,211) 01 July 2021 BNY Mellon USD (13,643) SEK 113,000 (430) 01 July 2021 BNY Mellon USD (2,261) SEK 35,500 (144) 01 July 2021 BNY Mellon USD (4,295) SEK 35,500 (144) 01 July 2021 BNY Mellon USD (4,295) SEK 35,500 (144) 01 July 2021 BNY Mellon USD (4,295) SEK 18,719 (72) 01 July 2021 BNY Mellon USD (1,653) SEK 13,657 (56) 01 July 2021 BNY Mellon USD (1,629)							
01 July 2021 BNY Mellon USD (24,463) NOK (207,291) (374) 01 July 2021 BNY Mellon USD (355,023) NOK (3,027,510) (3,198) 01 July 2021 BNY Mellon USD (38,49,464) EEK (31,696,779) (111,211) 01 July 2021 BNY Mellon USD (1,3643) SEK (113,000) (430) 01 July 2021 BNY Mellon USD (4,295) SEK (61,633) (201) 01 July 2021 BNY Mellon USD (2,261) SEK (13,500) (144) 01 July 2021 BNY Mellon USD (2,261) SEK (18,719) (72) 01 July 2021 BNY Mellon USD (4,841) SEK (14,000) (164) 01 July 2021 BNY Mellon USD (16,53) SEK (13,657) (56) 01 July 2021 BNY Mellon USD (10,429) SEK (14,000) (164) 01 July 2021 BNY Mellon USD (16,53) SEK (13,303) (6221) 01 July 2021 BNY Mellon USD (16,53) SEK (13,303) (7) 01 July 2021 BNY Mellon USD (15,311) SEK (1	•						, ,
01 July 2021 BNY Mellon USD (355,023) NOK 3,027,510 (3,198) 01 July 2021 BNY Mellon USD (3,849,464) SEK 31,969,779 (111,211) 01 July 2021 BNY Mellon USD (13,643) SEK 113,000 (430) 01 July 2021 BNY Mellon USD (7,408) SEK 61,633 (201) 01 July 2021 BNY Mellon USD (4,295) SEK 35,500 (144) 01 July 2021 BNY Mellon USD (4,295) SEK 18,719 (72) 01 July 2021 BNY Mellon USD (4,841) SEK 40,000 (164) 01 July 2021 BNY Mellon USD (1,653) SEK 13,657 (56) 01 July 2021 BNY Mellon USD (167,504) SEK 13,657 (56) 01 July 2021 BNY Mellon USD (10,429) SEK 13,657 (56) 01 July 2021 BNY Mellon USD (21,531)	•					,	
01 July 2021 BNY Mellon USD (3,849,464) SEK 31,969,779 (111,211) 01 July 2021 BNY Mellon USD (13,643) SEK 113,000 (430) 01 July 2021 BNY Mellon USD (7,408) SEK 61,633 (201) 01 July 2021 BNY Mellon USD (4,295) SEK 35,500 (144) 01 July 2021 BNY Mellon USD (2,261) SEK 18,719 (72) 01 July 2021 BNY Mellon USD (1,653) SEK 13,657 (56) 01 July 2021 BNY Mellon USD (1,653) SEK 13,657 (56) 01 July 2021 BNY Mellon USD (10,429) SEK 86,689 (292) 01 July 2021 BNY Mellon USD (167,504) SEK 13,657 (56) 01 July 2021 BNY Mellon USD (167,504) SEK 13,657 (56) 01 July 2021 BNY Mellon USD (15,296)	•						, ,
01 July 2021 BNY Mellon USD (13,643) SEK 113,000 (430) 01 July 2021 BNY Mellon USD (7,408) SEK 61,633 (201) 01 July 2021 BNY Mellon USD (4,295) SEK 35,500 (144) 01 July 2021 BNY Mellon USD (2,261) SEK 18,719 (72) 01 July 2021 BNY Mellon USD (4,841) SEK 40,000 (164) 01 July 2021 BNY Mellon USD (1,653) SEK 40,000 (164) 01 July 2021 BNY Mellon USD (1,653) SEK 40,000 (164) 01 July 2021 BNY Mellon USD (1,629) SEK 86,689 (292) 01 July 2021 BNY Mellon USD (167,504) SEK 13,79,306 (6,221) 01 July 2021 BNY Mellon USD (167,504) SEK 16,379,306 (6,221) 01 July 2021 BNY Mellon USD (1,531)	•						
01 July 2021 BNY Mellon USD (7,408) SEK 61,633 (201) 01 July 2021 BNY Mellon USD (4,295) SEK 35,500 (144) 01 July 2021 BNY Mellon USD (2,261) SEK 18,719 (72) 01 July 2021 BNY Mellon USD (4,841) SEK 40,000 (164) 01 July 2021 BNY Mellon USD (1,653) SEK 13,657 (56) 01 July 2021 BNY Mellon USD (10,429) SEK 86,689 (292) 01 July 2021 BNY Mellon USD (167,504) SEK 13,79,306 (6,221) 01 July 2021 BNY Mellon USD (20,102) SEK 168,152 (440) 01 July 2021 BNY Mellon USD (15,296) SEK 13,031 (7) 01 July 2021 BNY Mellon USD (13,100) SEK 132,062 146 01 July 2021 BNY Mellon USD (14,761) S	•						
01 July 2021 BNY Mellon USD (4,295) SEK 35,500 (144) 01 July 2021 BNY Mellon USD (2,261) SEK 18,719 (72) 01 July 2021 BNY Mellon USD (4,841) SEK 40,000 (164) 01 July 2021 BNY Mellon USD (1,653) SEK 13,657 (56) 01 July 2021 BNY Mellon USD (167,504) SEK 86,689 (292) 01 July 2021 BNY Mellon USD (167,504) SEK 13,79,306 (6,221) 01 July 2021 BNY Mellon USD (20,102) SEK 168,152 (440) 01 July 2021 BNY Mellon USD (1,531) SEK 13,031 (7) 01 July 2021 BNY Mellon USD (15,296) SEK 132,062 146 01 July 2021 BNY Mellon USD (13,100) SEK 125,020 (142) 01 July 2021 BNY Mellon USD (14,761) <td< td=""><td>•</td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	•						
01 July 2021 BNY Mellon USD (2,261) SEK (18,719) (72) 01 July 2021 BNY Mellon USD (4,841) SEK (40,000) (164) 01 July 2021 BNY Mellon USD (1,653) SEK (13,657) (56) 01 July 2021 BNY Mellon USD (10,429) SEK (86,689) (292) 01 July 2021 BNY Mellon USD (167,504) SEK (13,379,306) (6,221) 01 July 2021 BNY Mellon USD (20,102) SEK (18,152) (440) 01 July 2021 BNY Mellon USD (15,31) SEK (13,303) (7) 01 July 2021 BNY Mellon USD (15,296) SEK (132,062) 146 01 July 2021 BNY Mellon USD (13,100) SEK (11,656) (44) 01 July 2021 BNY Mellon USD (27,832) SEK (236,958) (124) 01 July 2021 BNY Mellon USD (27,832) SEK (236,958) (124) 02 August 2021 BNY Mellon SEK (11,365) USD (13,283) 736 02 August 2021 BNY Mellon SEK (11,365) USD (13,288) </td <td>•</td> <td></td> <td>USD</td> <td></td> <td>SEK</td> <td></td> <td>, ,</td>	•		USD		SEK		, ,
01 July 2021 BNY Mellon USD (4,841) SEK 40,000 (164) 01 July 2021 BNY Mellon USD (1,653) SEK 13,657 (56) 01 July 2021 BNY Mellon USD (10,429) SEK 86,689 (292) 01 July 2021 BNY Mellon USD (167,504) SEK 13,79,306 (6,221) 01 July 2021 BNY Mellon USD (20,102) SEK 168,152 (440) 01 July 2021 BNY Mellon USD (1,531) SEK 13,031 (7) 01 July 2021 BNY Mellon USD (15,296) SEK 132,062 146 01 July 2021 BNY Mellon USD (13,100) SEK 111,656 (44) 01 July 2021 BNY Mellon USD (14,761) SEK 125,020 (142) 01 July 2021 BNY Mellon USD (14,761) SEK 125,020 (142) 01 July 2021 BNY Mellon USD (13,100)		BNY Mellon	USD	(2,261)	SEK	18,719	(72)
01 July 2021 BNY Mellon USD (10,429) SEK 86,689 (292) 01 July 2021 BNY Mellon USD (167,504) SEK 1,379,306 (6,221) 01 July 2021 BNY Mellon USD (20,102) SEK 168,152 (440) 01 July 2021 BNY Mellon USD (15,296) SEK 132,062 146 01 July 2021 BNY Mellon USD (13,100) SEK 111,656 (44) 01 July 2021 BNY Mellon USD (14,761) SEK 125,020 (142) 01 July 2021 BNY Mellon USD (27,832) SEK 125,020 (142) 01 July 2021 BNY Mellon USD (27,832) SEK 236,958 (124) 01 July 2021 BNY Mellon USD (27,832) SEK 226,958 (124) 02 August 2021 BNY Mellon SEK (115,405) USD 13,547 48 02 August 2021 BNY Mellon USD (41,777,715)	•		USD		SEK		, ,
01 July 2021 BNY Mellon USD (10,429) SEK 86,689 (292) 01 July 2021 BNY Mellon USD (167,504) SEK 1,379,306 (6,221) 01 July 2021 BNY Mellon USD (20,102) SEK 168,152 (440) 01 July 2021 BNY Mellon USD (15,296) SEK 132,062 146 01 July 2021 BNY Mellon USD (13,100) SEK 111,656 (44) 01 July 2021 BNY Mellon USD (14,761) SEK 125,020 (142) 01 July 2021 BNY Mellon USD (27,832) SEK 125,020 (142) 01 July 2021 BNY Mellon USD (27,832) SEK 236,958 (124) 01 July 2021 BNY Mellon USD (27,832) SEK 226,958 (124) 02 August 2021 BNY Mellon SEK (115,405) USD 13,547 48 02 August 2021 BNY Mellon USD (41,777,715)	01 July 2021	BNY Mellon	USD	(1,653)	SEK	13,657	(56)
01 July 2021 BNY Mellon USD (167,504) SEK (1,379,306) (6,221) 01 July 2021 BNY Mellon USD (20,102) SEK (168,152) (440) 01 July 2021 BNY Mellon USD (1,531) SEK (13,031) (7) 01 July 2021 BNY Mellon USD (15,296) SEK (132,062) 146 01 July 2021 BNY Mellon USD (13,100) SEK (111,656) (444) 01 July 2021 BNY Mellon USD (14,761) SEK (155,020) (142) 01 July 2021 BNY Mellon USD (27,832) SEK (236,958) (124) 01 July 2021 BNY Mellon USD (27,832) SEK (236,958) (124) 02 August 2021 BNY Mellon NOK (1,136,956) USD (132,883) 736 02 August 2021 BNY Mellon SEK (115,405) USD (132,883) 736 02 August 2021 BNY Mellon USD (41,777,715) EUR (35,43,862) (190,300) 02 August 2021 BNY Mellon USD (131,913) EUR (10,651) (47,388) 02 August 2021 BNY Mellon USD (27,735	01 July 2021	BNY Mellon	USD		SEK	86,689	(292)
01 July 2021 BNY Mellon USD (1,531) SEK 13,031 (7) 01 July 2021 BNY Mellon USD (15,296) SEK 132,062 146 01 July 2021 BNY Mellon USD (13,100) SEK 111,656 (44) 01 July 2021 BNY Mellon USD (14,761) SEK 125,020 (142) 01 July 2021 BNY Mellon USD (27,832) SEK 125,020 (142) 01 July 2021 BNY Mellon USD (27,832) SEK 125,020 (142) 01 July 2021 BNY Mellon USD (27,832) SEK 125,020 (142) 01 July 2021 BNY Mellon USD (27,832) SEK 236,958 (124) 02 August 2021 BNY Mellon SEK (115,405) USD 132,883 736 02 August 2021 BNY Mellon USD (41,777,715) EUR 35,043,862 (190,300) 02 August 2021 BNY Mellon USD (131,	01 July 2021	BNY Mellon	USD	(167,504)		1,379,306	(6,221)
01 July 2021 BNY Mellon USD (15,296) SEK 132,062 146 01 July 2021 BNY Mellon USD (13,100) SEK 111,656 (44) 01 July 2021 BNY Mellon USD (14,761) SEK 125,020 (142) 01 July 2021 BNY Mellon USD (27,832) SEK 236,958 (124) 02 August 2021 BNY Mellon NOK (1,136,956) USD 132,883 736 02 August 2021 BNY Mellon SEK (115,405) USD 13,547 48 02 August 2021 BNY Mellon SEK (36,932) USD 4,319 1 02 August 2021 BNY Mellon USD (41,777,715) EUR 35,043,862 (190,300) 02 August 2021 BNY Mellon USD (10,403,244) EUR 8,726,419 (47,388) 02 August 2021 BNY Mellon USD (131,913) EUR 110,651 (601) 02 August 2021 BNY Mellon USD (27,735,973) NOK 237,014,987 (188,052) 02 August 2021 BNY Mellon USD (3,944,580) NOK 857,148,990 (680,078) 02 August 2021 BNY Mellon USD (2	01 July 2021	BNY Mellon	USD	(20,102)	SEK	168,152	(440)
01 July 2021 BNY Mellon USD (15,296) SEK 132,062 146 01 July 2021 BNY Mellon USD (13,100) SEK 111,656 (44) 01 July 2021 BNY Mellon USD (14,761) SEK 125,020 (142) 01 July 2021 BNY Mellon USD (27,832) SEK 125,020 (142) 02 August 2021 BNY Mellon USD (27,832) SEK 236,958 (124) 02 August 2021 BNY Mellon NOK (1,136,956) USD 132,883 736 02 August 2021 BNY Mellon SEK (15,405) USD 13,547 48 02 August 2021 BNY Mellon USD (41,777,715) EUR 35,043,862 (190,300) 02 August 2021 BNY Mellon USD (10,403,244) EUR 8,726,419 (47,388) 02 August 2021 BNY Mellon USD (131,913) EUR 110,651 (601) 02 August 2021 BNY Mellon USD <td>01 July 2021</td> <td>BNY Mellon</td> <td>USD</td> <td>(1,531)</td> <td>SEK</td> <td>13,031</td> <td>(7)</td>	01 July 2021	BNY Mellon	USD	(1,531)	SEK	13,031	(7)
01 July 2021 BNY Mellon USD (14,761) SEK 125,020 (142) 01 July 2021 BNY Mellon USD (27,832) SEK 236,958 (124) 02 August 2021 BNY Mellon NOK (1,136,956) USD 132,883 736 02 August 2021 BNY Mellon SEK (115,405) USD 13,547 48 02 August 2021 BNY Mellon SEK (36,932) USD 4,319 1 02 August 2021 BNY Mellon USD (41,777,715) EUR 35,043,862 (190,300) 02 August 2021 BNY Mellon USD (10,403,244) EUR 8,726,419 (47,388) 02 August 2021 BNY Mellon USD (131,913) EUR 110,651 (601) 02 August 2021 BNY Mellon USD (27,735,973) NOK 237,014,987 (188,052) 02 August 2021 BNY Mellon USD (3,944,580) NOK 33,708,018 (26,744) 02 August 2021 BNY Mellon<	01 July 2021	BNY Mellon				132,062	146
01 July 2021 BNY Mellon USD (27,832) SEK 236,958 (124) 02 August 2021 BNY Mellon NOK (1,136,956) USD 132,883 736 02 August 2021 BNY Mellon SEK (115,405) USD 13,547 48 02 August 2021 BNY Mellon SEK (36,932) USD 4,319 1 02 August 2021 BNY Mellon USD (41,777,715) EUR 35,043,862 (190,300) 02 August 2021 BNY Mellon USD (10,403,244) EUR 8,726,419 (47,388) 02 August 2021 BNY Mellon USD (131,913) EUR 110,651 (601) 02 August 2021 BNY Mellon USD (27,735,973) NOK 237,014,987 (188,052) 02 August 2021 BNY Mellon USD (100,305,309) NOK 857,148,990 (680,078) 02 August 2021 BNY Mellon USD (3,944,580) NOK 33,708,018 (26,744) 02 August 2021	01 July 2021	BNY Mellon	USD	(13,100)	SEK	111,656	(44)
02 August 2021 BNY Mellon NOK (1,136,956) USD 132,883 736 02 August 2021 BNY Mellon SEK (115,405) USD 13,547 48 02 August 2021 BNY Mellon SEK (36,932) USD 4,319 1 02 August 2021 BNY Mellon USD (41,777,715) EUR 35,043,862 (190,300) 02 August 2021 BNY Mellon USD (10,403,244) EUR 8,726,419 (47,388) 02 August 2021 BNY Mellon USD (131,913) EUR 110,651 (601) 02 August 2021 BNY Mellon USD (27,735,973) NOK 237,014,987 (188,052) 02 August 2021 BNY Mellon USD (100,305,309) NOK 857,148,990 (680,078) 02 August 2021 BNY Mellon USD (3,944,580) NOK 33,708,018 (26,744) 02 August 2021 BNY Mellon USD (4,031,134) SEK 34,339,894 (14,514) 02 August 2021 <td>01 July 2021</td> <td>BNY Mellon</td> <td>USD</td> <td>(14,761)</td> <td>SEK</td> <td>125,020</td> <td>(142)</td>	01 July 2021	BNY Mellon	USD	(14,761)	SEK	125,020	(142)
02 August 2021 BNY Mellon SEK (115,405) USD 13,547 48 02 August 2021 BNY Mellon SEK (36,932) USD 4,319 1 02 August 2021 BNY Mellon USD (41,777,715) EUR 35,043,862 (190,300) 02 August 2021 BNY Mellon USD (10,403,244) EUR 8,726,419 (47,388) 02 August 2021 BNY Mellon USD (131,913) EUR 110,651 (601) 02 August 2021 BNY Mellon USD (27,735,973) NOK 237,014,987 (188,052) 02 August 2021 BNY Mellon USD (100,305,309) NOK 857,148,990 (680,078) 02 August 2021 BNY Mellon USD (3,944,580) NOK 857,148,990 (680,078) 02 August 2021 BNY Mellon USD (290,758) NOK 2,499,500 (244) 02 August 2021 BNY Mellon USD (4,031,134) SEK 34,339,894 (14,514) 02 August 202	01 July 2021	BNY Mellon	USD	(27,832)	SEK	236,958	(124)
02 August 2021 BNY Mellon SEK (36,932) USD 4,319 1 02 August 2021 BNY Mellon USD (41,777,715) EUR 35,043,862 (190,300) 02 August 2021 BNY Mellon USD (10,403,244) EUR 8,726,419 (47,388) 02 August 2021 BNY Mellon USD (131,913) EUR 110,651 (601) 02 August 2021 BNY Mellon USD (27,735,973) NOK 237,014,987 (188,052) 02 August 2021 BNY Mellon USD (100,305,309) NOK 857,148,990 (680,078) 02 August 2021 BNY Mellon USD (3,944,580) NOK 33,708,018 (26,744) 02 August 2021 BNY Mellon USD (290,758) NOK 2,499,500 (244) 02 August 2021 BNY Mellon USD (4,031,134) SEK 34,339,894 (14,514) 02 August 2021 BNY Mellon USD (8,487) SEK 72,529 (4)	02 August 2021	BNY Mellon	NOK	(1,136,956)	USD	132,883	736
02 August 2021 BNY Mellon SEK (36,932) USD 4,319 1 02 August 2021 BNY Mellon USD (41,777,715) EUR 35,043,862 (190,300) 02 August 2021 BNY Mellon USD (10,403,244) EUR 8,726,419 (47,388) 02 August 2021 BNY Mellon USD (131,913) EUR 110,651 (601) 02 August 2021 BNY Mellon USD (27,735,973) NOK 237,014,987 (188,052) 02 August 2021 BNY Mellon USD (100,305,309) NOK 857,148,990 (680,078) 02 August 2021 BNY Mellon USD (3,944,580) NOK 33,708,018 (26,744) 02 August 2021 BNY Mellon USD (290,758) NOK 2,499,500 (244) 02 August 2021 BNY Mellon USD (4,031,134) SEK 34,339,894 (14,514) 02 August 2021 BNY Mellon USD (8,487) SEK 72,529 (4)	02 August 2021	BNY Mellon	SEK	(115,405)	USD	13,547	48
02 August 2021 BNY Mellon USD (10,403,244) EUR 8,726,419 (47,388) 02 August 2021 BNY Mellon USD (131,913) EUR 110,651 (601) 02 August 2021 BNY Mellon USD (27,735,973) NOK 237,014,987 (188,052) 02 August 2021 BNY Mellon USD (100,305,309) NOK 857,148,990 (680,078) 02 August 2021 BNY Mellon USD (3,944,580) NOK 33,708,018 (26,744) 02 August 2021 BNY Mellon USD (290,758) NOK 2,499,500 (244) 02 August 2021 BNY Mellon USD (4,031,134) SEK 34,339,894 (14,514) 02 August 2021 BNY Mellon USD (8,487) SEK 72,529 (4)	02 August 2021	BNY Mellon	SEK		USD	4,319	1
02 August 2021 BNY Mellon USD (131,913) EUR 110,651 (601) 02 August 2021 BNY Mellon USD (27,735,973) NOK 237,014,987 (188,052) 02 August 2021 BNY Mellon USD (100,305,309) NOK 857,148,990 (680,078) 02 August 2021 BNY Mellon USD (3,944,580) NOK 33,708,018 (26,744) 02 August 2021 BNY Mellon USD (290,758) NOK 2,499,500 (244) 02 August 2021 BNY Mellon USD (4,031,134) SEK 34,339,894 (14,514) 02 August 2021 BNY Mellon USD (8,487) SEK 72,529 (4)	02 August 2021	BNY Mellon	USD	(41,777,715)	EUR	35,043,862	(190,300)
02 August 2021 BNY Mellon USD (27,735,973) NOK 237,014,987 (188,052) 02 August 2021 BNY Mellon USD (100,305,309) NOK 857,148,990 (680,078) 02 August 2021 BNY Mellon USD (3,944,580) NOK 33,708,018 (26,744) 02 August 2021 BNY Mellon USD (290,758) NOK 2,499,500 (244) 02 August 2021 BNY Mellon USD (4,031,134) SEK 34,339,894 (14,514) 02 August 2021 BNY Mellon USD (8,487) SEK 72,529 (4)	02 August 2021	BNY Mellon	USD	(10,403,244)	EUR	8,726,419	(47,388)
02 August 2021 BNY Mellon USD (100,305,309) NOK 857,148,990 (680,078) (680,078) 02 August 2021 BNY Mellon USD (3,944,580) NOK 33,708,018 (26,744) (26,744) 02 August 2021 BNY Mellon USD (290,758) NOK 2,499,500 (244) (244) 02 August 2021 BNY Mellon USD (4,031,134) SEK 34,339,894 (14,514) (14,514) 02 August 2021 BNY Mellon USD (8,487) SEK 72,529 (4)	02 August 2021	BNY Mellon	USD	(131,913)	EUR	110,651	(601)
02 August 2021 BNY Mellon USD (3,944,580) NOK 33,708,018 (26,744) 02 August 2021 BNY Mellon USD (290,758) NOK 2,499,500 (244) 02 August 2021 BNY Mellon USD (4,031,134) SEK 34,339,894 (14,514) 02 August 2021 BNY Mellon USD (8,487) SEK 72,529 (4)	02 August 2021	BNY Mellon	USD	(27,735,973)	NOK	237,014,987	(188,052)
02 August 2021 BNY Mellon USD (290,758) NOK 2,499,500 (244) 02 August 2021 BNY Mellon USD (4,031,134) SEK 34,339,894 (14,514) 02 August 2021 BNY Mellon USD (8,487) SEK 72,529 (4)	02 August 2021	BNY Mellon	USD	(100,305,309)	NOK	857,148,990	(680,078)
02 August 2021 BNY Mellon USD (4,031,134) SEK 34,339,894 (14,514) 02 August 2021 BNY Mellon USD (8,487) SEK 72,529 (4)	02 August 2021	BNY Mellon	USD	(3,944,580)	NOK	33,708,018	(26,744)
02 August 2021 BNY Mellon USD (8,487) SEK 72,529 (4)	02 August 2021	BNY Mellon	USD	(290,758)		2,499,500	(244)
<u> </u>	02 August 2021	BNY Mellon	USD	(4,031,134)	SEK	34,339,894	(14,514)
Total unrealised loss on forward foreign currency contracts (5,568,002)	02 August 2021	BNY Mellon	USD	(8,487)	SEK	72,529	(4)
	Total unrealised loss on forward foreign curren	cy contracts				_	$(5,\overline{568,002})$

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(d) Foreign currency risk (Continued)

As at 30 June 2020 the following forward foreign currency contracts were held by the Funds:

Harvest Equity Kernel

Harvest Equity Kernel				Dunahasa		Unnaglicad
Maturity Date	Counterparty	Sale Currency	Amount	Purchase Currency	Amount	Unrealised gain/(loss) USD
02 July 2020	BNY Mellon	AUD	(794,742)	NOK	5,200,950	(8,059)
02 July 2020	BNY Mellon	AUD	(5,315,591)	NOK	34,786,288	(53,901)
02 July 2020	BNY Mellon	AUD	(67,353)	NOK	441,733	(583)
02 July 2020	BNY Mellon	AUD	(983,534)	NOK	6,450,483	(8,518)
02 July 2020	BNY Mellon	CAD	(1,032,138)	NOK	7,417,561	11,090
02 July 2020	BNY Mellon	CAD	(7,196,064)	NOK	51,715,236	77,322
02 July 2020	BNY Mellon	CHF	(487,136)	NOK	4,972,734	1,345
02 July 2020	BNY Mellon	CHF	(3,491,976)	NOK	35,646,437	9,645
02 July 2020	BNY Mellon	CHF	(46,282)	NOK	451,858	(2,007)
02 July 2020 02 July 2020	BNY Mellon BNY Mellon	CHF CNY	(292,005)	NOK USD	2,850,870 177,712	(12,664) (403)
02 July 2020 02 July 2020	BNY Mellon	CNY	(1,259,014) (8,824,338)	USD	1,245,569	(2,825)
02 July 2020 02 July 2020	BNY Mellon	CNY	(3,028,119)	USD	421,157	(7,236)
02 July 2020	BNY Mellon	CNY	(21,711,880)	USD	3,019,733	(51,884)
02 July 2020	BNY Mellon	EUR	(448,576)	NOK	4,888,001	2,852
02 July 2020	BNY Mellon	EUR	(3,127,474)	NOK	34,079,145	19,881
02 July 2020	BNY Mellon	EUR	(35,394)	NOK	372,461	(1,145)
02 July 2020	BNY Mellon	EUR	(323,013)	NOK	3,399,183	(10,447)
02 July 2020	BNY Mellon	GBP	(72,595)	NOK	879,681	1,488
02 July 2020	BNY Mellon	GBP	(520,391)	NOK	6,305,884	10,667
02 July 2020	BNY Mellon	HKD	(477,470)	USD	61,584	(21)
02 July 2020	BNY Mellon	HKD	(5,042,149)	USD	650,331	(226)
02 July 2020	BNY Mellon	HKD	(3,653,240)	USD	470,763	(591)
02 July 2020	BNY Mellon	HKD	(24,379,907)	USD	3,141,639	(3,944)
02 July 2020 02 July 2020	BNY Mellon BNY Mellon	INR INR	(8,290,058) (65,751,057)	USD USD	108,903 863,745	(857) (6,799)
02 July 2020 02 July 2020	BNY Mellon	JPY	(71,947,231)	NOK	6,603,632	17,630
02 July 2020 02 July 2020	BNY Mellon	JPY	(494,279,298)	NOK	45,367,119	121,119
02 July 2020	BNY Mellon	JPY	(83,809,399)	NOK	7,546,657	5,200
02 July 2020	BNY Mellon	JPY	(596,954,208)	NOK	53,753,024	37,034
02 July 2020	BNY Mellon	JPY	(15,775,153)	NOK	1,356,699	(5,590)
02 July 2020	BNY Mellon	JPY	(97,507,948)	NOK	8,385,905	(34,551)
02 July 2020	BNY Mellon	KRW	(212,430,205)	USD	171,345	(5,402)
02 July 2020	BNY Mellon		(1,504,542,875)	USD	1,213,556	(38,263)
02 July 2020	BNY Mellon	NOK	(796,965)	AUD	123,307	2,285
02 July 2020	BNY Mellon	NOK	(6,721,886)	AUD	1,040,013	19,271
02 July 2020	BNY Mellon	NOK	(4,845,718)	AUD	730,118	387
02 July 2020	BNY Mellon	NOK	(34,514,885)	AUD	5,200,453	2,760
02 July 2020 02 July 2020	BNY Mellon BNY Mellon	NOK NOK	(1,381,232)	CAD CAD	199,982 1,262,517	3,653 23,056
02 July 2020 02 July 2020	BNY Mellon	NOK	(8,719,913) (6,036,329)	CAD	853,686	1,065
02 July 2020 02 July 2020	BNY Mellon	NOK	(42,995,323)	CAD	6,080,601	7,592
02 July 2020	BNY Mellon	NOK	(5,079,936)	CHF	497,414	(1,611)
02 July 2020	BNY Mellon	NOK	(36,183,162)	CHF	3,542,957	(11,475)
02 July 2020	BNY Mellon	NOK	(2,314,145)	CHF	239,483	12,868
02 July 2020	BNY Mellon	NOK	(344,656)	CHF	35,348	1,580
02 July 2020	BNY Mellon	NOK	(1,225,947)	EUR	113,137	(7)
02 July 2020	BNY Mellon	NOK	(8,741,444)	EUR	806,708	(47)
02 July 2020	BNY Mellon	NOK	(4,034,515)	EUR	370,037	(2,594)
02 July 2020	BNY Mellon	NOK	(28,736,884)	EUR	2,635,686	(18,477)
02 July 2020	BNY Mellon	NOK	(879,681)	GBP	73,860	75 540
02 July 2020	BNY Mellon	NOK	(6,305,884)	GBP	529,459	540
02 July 2020	BNY Mellon	NOK	(413,674)	JPY JPY	4,578,006 83,816,945	(446)
02 July 2020 02 July 2020	BNY Mellon BNY Mellon	NOK NOK	(7,546,657) (53,753,024)	JPY JPY	83,816,945 597,007,961	(5,360) (38,176)
02 July 2020 02 July 2020	BNY Mellon	NOK NOK	(945,875)	SEK	907,756	(613)
02 July 2020 02 July 2020	BNY Mellon	NOK	(5,679,158)	SEK	5,450,288	(3,684)
02 July 2020 02 July 2020	BNY Mellon	NOK	(383,977)	USD	41,420	1,617
02 July 2020	BNY Mellon	NOK	(2,701,761)	USD	279,285	(779)
02 July 2020	BNY Mellon	NOK	(19,614,426)	USD	2,027,571	(5,659)
			, in the second of			

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(d) Foreign currency risk (Continued)

Harvest Equity Kernel (continued)

(Purchase		Unrealised
Maturity Date	Counterparty	Sale Currency	Amount	Currency	Amount	gain/(loss) USD
02 July 2020	BNY Mellon	NOK	(59,357,663)	USD	6,126,547	(26,465)
02 July 2020	BNY Mellon	NOK	(417,575,600)	USD	43,099,684	(186,176)
02 July 2020	BNY Mellon	NOK	(2,853,069)	USD	293,411	(2,338)
02 July 2020	BNY Mellon	SEK	(917,924)	NOK	945,875	(478)
02 July 2020	BNY Mellon	SEK	(5,511,339)	NOK	5,679,158	(2,869)
02 July 2020	BNY Mellon	TWD	(2,672,391)	USD	90,192	(507)
02 July 2020	BNY Mellon	TWD	(17,953,147)	USD	605,911	(3,403)
02 July 2020	BNY Mellon	TWD	(8,612,107)	USD	286,927	(5,361)
02 July 2020	BNY Mellon	TWD	(53,159,220)	USD	1,771,088	(33,091)
02 July 2020	BNY Mellon	USD	(103,826)	CNY	735,957	291
02 July 2020	BNY Mellon	USD	(731,047)	CNY	5,181,924	2,048
02 July 2020	BNY Mellon	USD	(501,508)	CNY	3,551,176	883
02 July 2020	BNY Mellon	USD	(3,580,609)	CNY	25,354,294	6,307
02 July 2020	BNY Mellon	USD	(532,967)	HKD	4,130,710	(8)
02 July 2020	BNY Mellon	USD	(3,796,198)	HKD	29,422,056	(59)
02 July 2020	BNY Mellon	USD	(109,757)	INR	8,290,058	4
02 July 2020	BNY Mellon	USD	(870,514)	INR	65,751,057	31
02 July 2020	BNY Mellon	USD	(176,837)	KRW	212,430,205	(89)
02 July 2020	BNY Mellon	USD	(1,252,450)	KRW	1,504,542,875	(631)
02 July 2020	BNY Mellon	USD	(156,921)	NOK	1,536,158	2,317
02 July 2020	BNY Mellon	USD	(1,130,662)	NOK	11,068,504	16,698
02 July 2020	BNY Mellon	USD	(5,852,946)	NOK	57,890,261	147,955
02 July 2020	BNY Mellon	USD	(40,451,985)	NOK	400,102,084	1,022,572
02 July 2020	BNY Mellon	USD	(199,798)	NOK	1,942,797	1,592
02 July 2020	BNY Mellon	USD	(85,951)	NOK	818,053	(1,152)
02 July 2020	BNY Mellon	USD	(662,288)	NOK	6,303,412	(8,877)
02 July 2020	BNY Mellon	USD	(41,724)	NOK	395,161	(762)
02 July 2020	BNY Mellon	USD	(210,820)	NOK	1,996,637	(3,849)
02 July 2020	BNY Mellon	USD	(274,525)	NOK	2,546,221	(10,584)
02 July 2020	BNY Mellon	USD	(746,857)	NOK	6,927,106	(28,794)
02 July 2020	BNY Mellon	USD	(221,853)	NOK	2,110,616	(3,067)
02 July 2020	BNY Mellon	USD	(930,195)	NOK	8,849,486	(12,858)
02 July 2020	BNY Mellon	USD	(79,971)	TWD	2,386,407	1,022
02 July 2020	BNY Mellon	USD	(259,154)	TWD	7,733,404	3,311
02 July 2020	BNY Mellon	USD	(301,630)	TWD	8,898,091	364
02 July 2020	BNY Mellon	USD	(2,148,439)	TWD	63,378,963	2,589
04 August 2020	BNY Mellon	AUD	(730,151)	NOK	4,845,718	(427)
04 August 2020	BNY Mellon	AUD	(5,200,688)	NOK	34,514,885	(3,041)
04 August 2020	BNY Mellon	CAD	(853,759)	NOK	6,036,329	(1,089)
04 August 2020	BNY Mellon BNY Mellon	CAD CHF	(6,081,117) (497,049)	NOK NOK	42,995,323 5,079,936	(7,758) 1,536
04 August 2020 04 August 2020	BNY Mellon	CHF		NOK	36,183,162	10,939
04 August 2020 04 August 2020	BNY Mellon	CNY	(3,540,358) (3,551,176)	USD	500,659	(815)
04 August 2020 04 August 2020	BNY Mellon	CNY	(25,354,294)	USD	3,574,552	(5,814)
04 August 2020 04 August 2020	BNY Mellon	EUR	(369,844)	NOK	4,034,515	2,552
04 August 2020 04 August 2020	BNY Mellon	EUR	(2,634,309)	NOK	28,736,884	18,171
04 August 2020	BNY Mellon	GBP	(73,858)	NOK	879,681	(80)
04 August 2020	BNY Mellon	GBP	(529,441)	NOK	6,305,884	(576)
04 August 2020	BNY Mellon	HKD	(4,130,710)	USD	532,830	(44)
04 August 2020	BNY Mellon	HKD	(29,422,056)	USD	3,795,219	(314)
04 August 2020	BNY Mellon	INR	(8,290,058)	USD	109,322	(71)
04 August 2020	BNY Mellon	INR	(65,751,057)	USD	867,070	(563)
04 August 2020	BNY Mellon	KRW	(212,430,205)	USD	176,807	(307)
04 August 2020	BNY Mellon		(1,504,542,875)	USD	1,252,241	(2,178)
04 August 2020	BNY Mellon	SEK	(907,662)	NOK	945,875	595
04 August 2020	BNY Mellon	SEK	(5,449,720)	NOK	5,679,158	3,574
04 August 2020	BNY Mellon	TWD	(8,898,091)	USD	302,728	(1,489)
04 August 2020	BNY Mellon	TWD	(63,378,963)	USD	2,156,260	(10,608)
04 August 2020	BNY Mellon	USD	(6,127,717)	NOK	59,357,663	26,118
04 August 2020	BNY Mellon	USD	(43,107,915)	NOK	417,575,600	183,736
Total unrealised gain on forward foreign curre		232	(.= , - 0 , , , 20)			1,135,791
20m. am cambea gam on for ward foreign curre	commune				_	1,100,171

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(d) Foreign currency risk (Continued)

Sector Healthcare Value Fund

Section areas value a unu				Purchase		Unrealised
Maturity Date		Sale Currency	Amount	Currency	Amount	gain/(loss) USD
01 July 2020	BNY Mellon	EUR	(142,422)	USD	161,291	1,326
01 July 2020	BNY Mellon	EUR	(6,887)	USD	7,799	64
01 July 2020	BNY Mellon	EUR	(1,180,242)	USD	1,336,610	10,995
01 July 2020 01 July 2020	BNY Mellon BNY Mellon	EUR EUR	(4,169,051) (212,927)	USD USD	4,700,188 240,054	17,626 900
01 July 2020 01 July 2020	BNY Mellon	EUR	(29,588,698)	USD	33,358,298	125,097
01 July 2020	BNY Mellon	NOK	(320,673)	USD	34,394	1,153
01 July 2020	BNY Mellon	NOK	(1,098,723)	USD	115,970	2,077
01 July 2020	BNY Mellon	NOK	(342,644)	USD	36,160	642
01 July 2020	BNY Mellon	NOK	(44,219)	USD	4,656	73
01 July 2020	BNY Mellon	NOK	(8,028,233)	USD	840,395	8,192
01 July 2020	BNY Mellon	NOK	(24,480,762)	USD	2,562,644	24,979
01 July 2020	BNY Mellon	NOK	(22,583)	USD	2,338	(3)
01 July 2020	BNY Mellon	NOK	(204,646,535)	USD	21,149,473	(64,095)
01 July 2020	BNY Mellon	NOK	(737,308,682)	USD	76,198,165	(230,923)
01 July 2020	BNY Mellon	NOK	(2,039,458)	USD	210,249	(1,160)
01 July 2020	BNY Mellon	NOK	(616,931)	USD	63,411	(540)
01 July 2020 01 July 2020	BNY Mellon BNY Mellon	NOK SEK	(281,049) (67,382)	USD USD	28,856 7,314	(277) 82
01 July 2020	BNY Mellon	SEK	(653,540)	USD	70,521	373
01 July 2020	BNY Mellon	SEK	(20,296,100)	USD	2,181,860	3,362
01 July 2020	BNY Mellon	SEK	(91,075)	USD	9,768	(8)
01 July 2020	BNY Mellon	SEK	(20,739)	USD	2,217	(9)
01 July 2020	BNY Mellon	SEK	(71,375)	USD	7,627	(34)
01 July 2020	BNY Mellon	SEK	(27,824)	USD	2,970	(17)
01 July 2020	BNY Mellon	SEK	(25,149)	USD	2,678	(21)
01 July 2020	BNY Mellon	USD	(4,418,239)	EUR	4,010,419	86,152
01 July 2020	BNY Mellon	USD	(225,594)	EUR	204,771	4,399
01 July 2020	BNY Mellon	USD	(22,033,800)	EUR	20,000,000	429,643
01 July 2020	BNY Mellon	USD	(189,201)	EUR	170,121	1,874
01 July 2020	BNY Mellon BNY Mellon	USD USD	(9,946) (1,019,222)	EUR EUR	8,943 916,440	99 10,098
01 July 2020 01 July 2020	BNY Mellon	USD	(1,019,222)	EUR	130,933	313
01 July 2020 01 July 2020	BNY Mellon	USD	(6,837)	EUR	6,100	15
01 July 2020	BNY Mellon	USD	(955,467)	EUR	852,500	2,037
01 July 2020	BNY Mellon	USD	(10,177,587)	EUR	9,000,000	(69,038)
01 July 2020	BNY Mellon	USD	(118,467)	NOK	1,160,665	1,847
01 July 2020	BNY Mellon	USD	(18,232,121)	NOK	180,084,124	435,319
01 July 2020	BNY Mellon	USD	(70,983,982)	NOK	701,130,086	1,694,849
01 July 2020	BNY Mellon	USD	(3,075,203)	NOK	29,821,754	16,107
01 July 2020	BNY Mellon	USD	(690,438)	NOK	6,695,519	3,616
01 July 2020	BNY Mellon	USD	(31,483)	NOK	300,000	(385)
01 July 2020 01 July 2020	BNY Mellon BNY Mellon	USD USD	(143,090) (23,951)	NOK NOK	1,363,485 229,914	(1,752) (118)
01 July 2020 01 July 2020	BNY Mellon	USD	(351,514)	NOK	3,378,372	(1,314)
01 July 2020	BNY Mellon	USD	(264,276)	NOK	2,519,725	(3,082)
01 July 2020	BNY Mellon	USD	(72,261)	NOK	693,333	(390)
01 July 2020	BNY Mellon	USD	(2,188,274)	NOK	20,996,228	(11,814)
01 July 2020	BNY Mellon	USD	(127,728)	NOK	1,229,332	(296)
01 July 2020	BNY Mellon	USD	(583,137)	NOK	5,595,125	(3,149)
01 July 2020	BNY Mellon		(47,207)	NOK	452,260	(326)
01 July 2020	BNY Mellon	USD	(55,756)	NOK	516,876	(2,177)
01 July 2020	BNY Mellon	USD	(196,331)	NOK	1,821,381	(7,528)
01 July 2020	BNY Mellon	USD	(2,234)	NOK	20,697	(89)
01 July 2020 01 July 2020	BNY Mellon BNY Mellon	USD USD	(2,135,428) (46,527)	NOK NOK	20,000,000	(62,237) (1,356)
01 July 2020 01 July 2020	BNY Mellon	USD	(82,589)	NOK NOK	435,759 785,857	(1,127)
01 July 2020 01 July 2020	BNY Mellon	USD	(4,522)	SEK	43,100	104
01 July 2020 01 July 2020	BNY Mellon	USD	(2,000,556)	SEK	19,183,530	58,523
01 July 2020	BNY Mellon	USD	(16,631)	SEK	156,815	201
01 July 2020	BNY Mellon	USD	(85,713)	SEK	809,169	1,140
01 July 2020	BNY Mellon	USD	(1,090)	SEK	10,000	(17)
01 July 2020	BNY Mellon	USD	(3,728)	SEK	34,170	(60)

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(d) Foreign currency risk (Continued)

Sector Healthcare Value Fund (continued)

				Purchase		Unrealised
Maturity Date	Counterparty	Sale Currency	Amount	Currency	Amount	gain/(loss) USD
01 July 2020	BNY Mellon	USD	(7,480)	SEK	68,951	(79)
01 July 2020	BNY Mellon	USD	(2,568)	SEK	24,000	8
01 July 2020	BNY Mellon	USD	(5,786)	SEK	54,360	49
01 July 2020	BNY Mellon	USD	(1,459)	SEK	13,700	11
01 July 2020	BNY Mellon	USD	(61,269)	SEK	576,816	644
01 July 2020	BNY Mellon	USD	(29,748)	SEK	275,600	(166)
01 July 2020	BNY Mellon	USD	(319)	SEK	2,973	_
04 August 2020	BNY Mellon	NOK	(398,742)	USD	41,347	8
04 August 2020	BNY Mellon	SEK	(8,526)	USD	916	-
04 August 2020	BNY Mellon	USD	(4,703,773)	EUR	4,169,051	(17,557)
04 August 2020	BNY Mellon	USD	(240,237)	EUR	212,927	(897)
04 August 2020	BNY Mellon	USD	(33,383,744)	EUR	29,588,698	(124,613)
04 August 2020	BNY Mellon	USD	(103,844)	NOK	1,006,440	497
04 August 2020	BNY Mellon	USD	(21,153,518)	NOK	204,646,535	62,967
04 August 2020	BNY Mellon	USD	(76,212,736)	NOK	737,308,682	226,859
04 August 2020	BNY Mellon	USD	(2,182,799)	SEK	20,296,100	(3,348)
04 August 2020	BNY Mellon	USD	(9,971)	SEK	92,858	_
Total unrealised gain on forward foreign curre	ncy contracts					2,624,318

(e) Credit risk

Credit risk is the risk that a counterparty will fail to discharge an obligation or commitment that is has entered into with the Funds, resulting in a financial loss to the Funds.

The Funds are exposed to credit risk associated with counterparties with whom it trades or holds assets, and will also be exposed to the risk of settlement default. All transactions in listed securities are settled/paid for upon delivery using approved brokers. The risk of default is considered minimal, as delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase once the securities have been received by the broker. The trade will fail if either party fails to meet its obligation.

Management of credit risk

The Investment Manager is complying with the Central Bank UCITS Regulations in terms of investment restrictions and otherwise with the investment policy of the Sub-Funds.

Exposure to credit risk

The Sub-Fund's maximum credit risk exposure at the Balance Sheet date is represented by the respective carrying amounts of the financial assets in the Balance Sheet with the exception of derivatives whose maximum credit risk exposure is notional exposure.

Derivative financial instruments

The Funds may also invest in financial derivative instruments for investment purposes and for efficient portfolio management ("EPM"), including (but not limited to) futures, forwards, options, contracts for difference and warrants.

All cleared derivative positions entered into on behalf of the Funds are cleared via Goldman Sachs as appointed Futures Commission Merchant ("FCMs"). Bilateral (non-cleared) derivatives face BNY as OTC credit counterparty.

Trade counterparty

The Funds mitigate counterparty risk by undertaking transactions with large and well capitalised counterparties. The Funds also seek to trade with more than one counterparty and have reduced the activity with counterparties when there have been questions raised regarding the robustness of counterparties in terms of credit risk.

Although it is the intention of the Investment Managers to follow a general policy of seeking to spread the Funds' capital at risk over a number of investments and counterparties, the Funds may at certain times hold relatively few positions with the result that a loss in any such position either to trading counterparty or settlement default could have a substantial adverse impact on a Fund's capital.

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(e) Credit risk (Continued)

	30 June 2021	30 June 2020
BNY Mellon	A	A
DNB	AA-	AA-
Goldman Sachs	A+	A+

As at 30 June 2021 and 30 June 2020, the Funds had not pledged any securities as collateral for contracts-for-difference trading.

(f) Fair value estimation

The Company used the following fair value hierarchy levels in categorising its financial instruments by source of inputs used to determine its fair value:

Level 1: The unadjusted quoted price in an active market for identical assets or liabilities that the entity can access at the measurement date.

Level 2: Inputs other than quoted prices included within Level 1 that are observable (i.e. developed using market data) for the asset or liability, either directly or indirectly.

Level 3: Inputs are unobserverable (i.e. for which market data is unavailable) for the asset or liability.

The determination of what constitutes 'observable' requires significant judgement by the Company. The Company considers observable data to be that market data that is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.

Investments classified as Level 3 are those for which a quoted price at period end was unavailable and evidence of a recent transaction at that date could not be ascertained. These investments represent collective investment schemes where the net asset value is calculated by an underlying administrator. The net asset values represent their best evidence of the fair value of these assets at period end, however due to the lack of quoted price and evidence of a recent transaction, a Level 3 classification is considered appropriate.

The level in the fair value hierarchy within which the fair value measurement is categorised is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses inputs that are unobservable, that measurement is a Level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement, considering factors specific to the asset or liability.

There were no significant transfers between levels during the period ended 30 June 2021 or 30 June 2020. Transfers between levels of the fair value hierarchy, for the purpose of disclosure in financial statements, are deemed to have occurred at the end of the reporting period.

The fair values of investments valued under Levels 1 to 3 as at 30 June 2021 are as follows overleaf:

Sector Healthcare Value Fund	Level 1	Level 2	Level 3	Total
	USD	USD	USD	USD
Financial assets at fair value through profit or loss				
Equity securities	465,410,187	_	_	465,410,187
Derivative instruments	_	1,158,129	_	1,158,129
Money market instrument	20,000,000	-	_	_
Financial liabilities at fair value through profit or loss				
Derivative instruments	_	(6,726,131)	_	(6,726,131)
Total	485,410,187	(5,568,002)	-	479,842,185

The categories of investments above comprise:

- Equity securities (which includes equities, money market funds, real estate investment trusts and rights).
- Derivative instruments (which includes forward foreign currency contracts, contracts-for-difference, futures and options).

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(f) Fair value estimation (Continued)

The fair values of investments valued under Levels 1 to 3 as at 30 June 2020 are as follows:

Harvest Equity Kernel	Level 1 USD	Level 2 USD	Level 3 USD	Total USD
Financial assets at fair value through profit or loss				
Equity securities	114,616,580	_	_	114,616,580
Derivative instruments	_	2,136,297	_	2,136,297
Financial liabilities at fair value through profit or loss				
Derivative instruments	_	(807,557)	_	(807,557)
Total	114,616,580	1,328,740	_	115,945,320
Sector Healthcare Value Fund	Level 1	Level 2	Level 3	Total
	USD	USD	USD	USD
Financial assets at fair value through profit or loss				
Equity securities	210,128,918	_	_	210,128,918
Derivative instruments	_	3,234,320	_	3,234,320
Financial liabilities at fair value through profit or loss				
Derivative instruments	_	(610,002)	_	(610,002)
Total	210,128,918	2,624,318	-	212,753,236

The categories of investments above comprise:

Derivative instruments (which includes forward foreign currency contracts, contracts-for-difference, futures and options).

[•] Equity securities (which includes equities, real estate investment trusts and rights).

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

8. Share Capital

The authorised share capital of the Company is 1,000,000,000,000,000 Shares of no par value initially designated as unclassified shares. The issued share capital of the Company is &2 represented by 2 shares (the "Subscriber Shares") issued for the purposes of the incorporation of the Company at an issue price of &1 per Share which are fully paid up and which are beneficially owned by Sector Asset Management AS and Prieren AS.

Sector Healthcare Value Fund may issue Class A EUR Shares, Class A USD Shares, Class A NOK Shares and Class A SEK Shares, (the "Class A Shares"), B EUR Shares, Class B USD Shares, Class B NOK Shares and Class B SEK (the "Class B Shares"), Class E EUR Shares, Class E USD Shares, Class, E SEK Shares and Class E NOK Shares and Class E USD Shares (the "Class E Shares"), Class X EUR Shares and Class X USD Shares (the "Class X Shares") and Y EUR Shares, Class Y GBP Shares and Class Y USD Shares (the "Class Y Shares").

Harvest Equity Kernel may have issued Class A EUR Shares, Class A USD Shares, Class A NOK Shares Hedged, Shares, Class A NOK Unhedged Shares and Class A SEK Shares (the "Class A Shares"), Class B Shares, which are comprised of Class B EUR Shares, Class B USD Shares, Class B NOK Hedged Shares, Class B NOK Unhedged Shares and Class B SEK (the "Class B Shares"), Class C EUR Shares, Class C USD Shares, Class C NOK Shares and Class C SEK Shares (the "Class C Shares"), Class P USD Shares, Class P NOK Hedged Shares and Class P NOK Unhedged Shares ("the Class P Shares") and Class O NOK Shares.

On a show of hands every holder who is present in person or by proxy shall have one vote and the holders of Subscriber Shares present or in person or by proxy shall have one vote.

The rights attached to any class may be varied or abrogated with the consent in writing of the holders of three-fourths in number of the issued Shares of that class, or with the sanction of a special resolution passed at a separate general meeting of the holders of the Shares of the class, and may be so varied or abrogated either whilst the Company is a going concern or during or in contemplation of a winding-up. The quorum at any such separate general meeting, other than an adjourned meeting, shall be two persons holding or representing by proxy at least one third of the issued Shares of the class in question and the quorum at an adjourned meeting shall be one person holding Shares of the class in question or his proxy.

Class O NOK Shares are only available for subscription by (i) other funds, (including sub-funds of the Company), or similar collective investment schemes that the Investment Manager manages; (ii) the Directors; (iii) any person or investor connected with any such person or entity referred to in parts (i) and (ii) including, without limitation, a trustee of a trust established by or for such an entity, (iv) any company, partnership or other entity controlled by the Investment Manager (v) any company, partnership or other entity which has been appointed or acts as investment manager or investment adviser of an entity referred to in part (i), (vi) any employee of the Investment Manager or (vii) any nominee of any of the foregoing.

The following are the share class transactions for the financial period ended 30 June 2021 were as follows:

	Harvest Equity Sector Healthcard		
	Kernel	Value Fund	
Class A EUR			
Shares in issue at beginning of period	_	11,959	
Number of shares issued	_	13,541	
Number of shares redeemed	_	(416)	
Number in issue at end of period	_	25,084	
Class A NOK			
Shares in issue at beginning of period	104,604	77,368	
Number of shares issued	1,887	224	
Number of shares redeemed	(106,491)	(1,371)	
Number in issue at end of period		76,221	
Class A USD			
Shares in issue at beginning of period	164	65,122	
Number of shares issued	_	14,158	
Number of shares redeemed	(164)	(18,154)	
Number in issue at end of period	_	61,126	

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

8. Share Capital (Continued)

8. Share Capital (Continued)	Harvest Equity Sec Kernel	tor Healthcare Value Fund
Class B EUR Shares in issue at beginning of period	_	2,107
Number of shares issued Number of shares redeemed	_	(1.257)
Number in issue at end of period		(1,357) 750
Transcer in issue at one or period		
Class B NOK		
Shares in issue at beginning of period Number of shares issued	_	490,694 55,348
Number of shares redeemed	_ _	(44,411)
Number in issue at end of period		501,631
CL D CDV		
Class B SEK Shares in issue at beginning of period	_	16,371
Number of shares issued	_	6,791
Number of shares redeemed		(2,018)
Number in issue at end of period		21,144
Class B USD		
Shares in issue at beginning of period	_	187,407
Number of shares issued	_	177,282
Number of shares redeemed		(63,022)
Number in issue at end of period		301,667
Class P NOK		
Shares in issue at beginning of period	640,164	_
Number of shares issued Number of shares redeemed	(640 164)	_
Number in issue at end of period	(640,164)	
Number in issue at the or period		
Class P NOK Unhedged		
Shares in issue at beginning of period	227,923	_
Number of shares issued Number of shares redeemed	2,505 (230,428)	_
Number in issue at end of period	(230,120)	
CI DIVID		
Class P USD Shares in issue at beginning of period	327	_
Number of shares issued	-	_
Number of shares redeemed	(327)	_
Number in issue at end of period		
Class X EUR		
Shares in issue at beginning of period	_	309,159
Number of shares issued	_	_
Number of shares redeemed		200 150
Number in issue at end of period		309,159
Class X USD		
Shares in issue at beginning of period	-	176,532
Number of shares issued Number of shares redeemed	_	97,554 (5.381)
Number in issue at end of period		(5,381)
v. in loode we that of period		200,703

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

8. Share Capital (Continued)

	Harvest Equity Sector Healthcare		
	Kernel	Value Fund	
Class E NOK			
Shares in issue at beginning of period	_	_	
Number of shares issued	_	310,166	
Number of shares redeemed	_	_	
Number in issue at end of period	_	310,166	
Class E USD			
Shares in issue at beginning of period	_	_	
Number of shares issued	_	15,000	
Number of shares redeemed	_	_	
Number in issue at end of period		15,000	
Class Y EUR			
Shares in issue at beginning of period	_	39,316	
Number of shares issued	_	1,205	
Number of shares redeemed	_	_	
Number in issue at end of period	_	40,521	
Class Y GBP			
Shares in issue at beginning of period	_	479,279	
Number of shares issued	_	145,859	
Number of shares redeemed		(3,843)	
Number in issue at end of period		621,295	
Class Y USD			
Shares in issue at beginning of period	_	419,660	
Number of shares issued	_	103,489	
Number of shares redeemed	_	(21,838)	
Number in issue at end of period		501,311	

The following are the share class transactions for the financial period ended 30 June 2020 were as follows:

	Harvest Equity Sector Healthcar		
	Kernel	Value Fund	
Class A EUR			
Shares in issue at beginning of period	_	17,800	
Number of shares issued	_	2,833	
Number of shares redeemed	_	(6,545)	
Number in issue at end of period	_	14,088	
Class A NOK			
Shares in issue at beginning of period	96,170	39,187	
Number of shares issued	21,338	39,386	
Number of shares redeemed	(26,925)	(1,452)	
Number in issue at end of period	90,583	77,121	
Class A USD			
Shares in issue at beginning of period	121	66,547	
Number of shares issued	1	4,085	
Number of shares redeemed	(115)	(8,937)	
Number in issue at end of period	7	61,695	

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

8. Share Capital (Continued)

8. Share Capital (Continued)	Harvest Equity Sect Kernel	or Healthcare Value Fund
Class B EUR		
Shares in issue at beginning of period	_	1,757
Number of shares issued	_	_
Number of shares redeemed		(72)
Number in issue at end of period		1,685
Class B NOK		
Shares in issue at beginning of period	_	402,316
Number of shares issued	_	182,887
Number of shares redeemed		(78,506)
Number in issue at end of period		506,697
Class B SEK		
Shares in issue at beginning of period	_	12,067
Number of shares issued	_	5,073
Number of shares redeemed		(2,492)
Number in issue at end of period		14,648
Class B USD		
Shares in issue at beginning of period	_	62,929
Number of shares issued	_	46,237
Number of shares redeemed		(20,526)
Number in issue at end of period	-	88,640
Class L NOK		
Shares in issue at beginning of period	_	24,461
Number of shares issued	_	1,000
Number of shares redeemed		(25,461)
Number in issue at end of period		
Class P NOK		
Shares in issue at beginning of period	682,819	_
Number of shares issued	53,374	_
Number of shares redeemed	(64,449)	
Number in issue at end of period	671,744	
Class P NOK Unhedged		
Shares in issue at beginning of period	296,293	_
Number of shares issued	160,763	_
Number of shares redeemed	(17,083)	
Number in issue at end of period	439,973	
Class P USD		
Shares in issue at beginning of period	405	_
Number of shares issued	(70)	_
Number of shares redeemed	(78)	
Number in issue at end of period	327	
Class X EUR		
Shares in issue at beginning of period	-	-
Number of shares issued	_	309,159
Number of shares redeemed		309,159
Number in issue at end of period		309,139

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

8. Share Capital (Continued)

•	Harvest Equity Sec	Harvest Equity Sector Healthcare		
	Kernel	Value Fund		
Class X USD				
Shares in issue at beginning of period	_	225,724		
Number of shares issued	_	5,356		
Number of shares redeemed	_	(15,414)		
Number in issue at end of period		215,666		

9. Investment Management Fees

From 5 February 2021, the Company has appointed Sector Funds Services AS as the Investment Manager. The Company had appointed Harvest Funds AS from 2 January 2020 up to 5 February 2021, (Sector Omega AS up to 1 January 2020) as Investment Manager to Harvest Equity Kernel and Sector Gamma AS as Investment Manager to Sector Healthcare Value Fund. Sigma Fondsforvaltning AS was the Investment Manager to Sector Sigma Nordic Fund.

Harvest Equity Kernel and Sector Healthcare Value Fund pays the Investment Manager a management fee per annum of the Net Asset Value of each of the following classes:

Harvest Equity Kernel		Sector Healthcare V	Sector Healthcare Value Fund		
Class	Management Fee	Class	Management Fee		
Class A Shares	Up to 1.50%	Class A Shares	Up to 1.0%		
Class B Shares	Up to 0.75%	Class B Shares	Up to 2.0%		
Class C Shares	Up to 0.50%	Class E Shares	Up to 1.0%		
Class P Shares	Up to 0.50%	Class X Shares	Up to 0.50%		
Class O Shares	Up to 3.00%	Class Y Shares	Up to 0.40%		

The Investment Manager does not charge a fee in respect of the Class L NOK Shares.

The total management fees accrued for the financial period ended 30 June 2021 were USD2,176,206 (30 June 2020: USD1,471,101) and the net amount outstanding at 30 June 2021 was USD412,503 (30 June 2020: USD346,472).

10. Incentive Fees/Performance Fees

The Investment Manager is also entitled to receive an incentive fee/performance fee ("Incentive Fee" / "Performance Fee"), as calculated for each Fund as disclosed below. The Incentive Fee/Performance Fee will be verified by the Depositary.

Harvest Equity Kernel

The Fund, in respect of the Class C Shares and Class O Shares pays the Investment Manager an incentive fee (the "Incentive Fee") equal to 10 per cent of the amount by which the Net Asset Value (before the deduction of any performance fee) of the relevant Class exceeds the MSCI ACWI Index ("Index") adjusted Prior High Net Asset Value ("Index adjusted Prior High Net Asset Value") (as defined below). No Incentive Fee is charged in respect of the Class A Shares, Class B Shares, Class P Shares and Class L NOK Shares.

The Incentive Fee is calculated on a share-by-share basis so that each share is charged a fee which equates precisely with that share's performance over each Calculation Year (as defined below). This method of calculation ensures that (i) any Incentive Fee paid to the Investment Manager is charged only to those shares which have outperformed their respective Prior High Net Asset Value over the course of a Calculation Year, (ii) all holders of shares have the same amount of capital per share at risk in the Fund, and (iii) all shares in a particular class have the same net asset value per share.

The Incentive Fee shall only be payable on the amount by which each share outperforms the previous high watermark or Index adjusted Prior High Net Asset Value for the relevant share. For each Calculation Year, an Incentive Fee will only be payable by a particular share if the net asset value of that share at the end of a Calculation Year is greater than the prevailing Prior High Net Asset Value for that share.

The "Prior High Net Asset Value" of each share is the highest net asset value per share on which Incentive Fee was paid in respect of any previous Calculation Year (or, if no Incentive Fee has yet been paid with respect to any such Calculation Year, the Initial Issue Price of the relevant share). The "Index adjusted Prior High Net Asset Value" of each share is the Prior High Net Asset Value adjusted by the performance of the Index for the relevant Calculation Year. The calculation year for the Incentive Fee shall be a calendar year, closing on the 31 December each year (or if the 31 December is not a Business Day, on the last Business Day of the year) (the "Calculation Year"). The Incentive Fee will accrue as at each valuation point and shall be payable annually in arrears (on or after the first business day of the following year).

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

10. Incentive Fees/Performance Fees (Continued)

Sector Healthcare Value Fund

The Fund, in respect of the Class A Shares, pays the Investment Manager a fee equal to 20% of the amount by which the net asset value (before the deduction of any performance fee) of the relevant share exceeds the MSCI Daily TR World Net Healthcare USD (the "Index"). In respect of Class E Shares, a fee equal to 20% of the amount by which the net asset value (before the deduction of any performance fee) of the relevant share exceeds the Index (the "Incentive Fee"). In respect of Class X Shares and Class Y Shares, a fee equal to 15% of the amount by which the net asset value (before the deduction of any performance fee) of the relevant share exceeds the Index (the "Incentive Fee").

The relevant share's subscription price or the initial issue price (where shares are issued during the initial offer year) is taken as the starting price for the purposes of determining the Incentive Fee. The Incentive Fee is accrued on a daily basis and reflected in the net asset value per share at each valuation point. The accrued Incentive Fee will only be paid to the Investment Manager once a shareholder redeems its investment in the Fund or when the Fund closes down where the performance of the relevant shares has exceeded the performance of the Index. The Incentive Fee may be payable even if the absolute return on the shareholder's investment is zero or negative. For example, if during the year of a shareholder's investment in the Fund, the net asset value per share on redemption is less than or equal to the net asset value per share that that shareholder paid on its initial subscription into the Fund, the Incentive Fee may still be payable if the net asset value per share on redemption exceeds the Index Net Asset Value per share, i.e. the Fund has outperformed the Index for the year of the shareholder's investment. No Incentive Fee will be charged in respect of the Class B Shares.

The Performance Fees accrued by the Company for the financial period ended 30 June 2021 was USD23,130 and the amount outstanding at 30 June 2021 was USD323,066. During the period ended 30 June 2020, there was a reversal of accrued Performance Fees which resulted in a net credit of USD106,438 to the profit and loss account with USD505,168 payable at the period end.

Equalisation Credit

The equalisation credit policy is applied to the calculation of the Incentive Fee payable for certain classes in each Fund (see the Fund's relevant Supplement for further details). The Incentive Fee is calculated on a share-by-share basis so that each relevant share is charged an Incentive Fee that equates precisely with that relevant share's performance. This method of calculation ensures that (i) the Incentive Fee is charged only to those relevant shares that have appreciated in value relative to the Index, (ii) all relevant shareholders have the same amount per relevant share of the relevant class at risk in the Fund, and (iii) all shares of the same class have the same net asset value per share. If a shareholder subscribes for relevant shares at a time when the net asset value per relevant share is other than the Index Net Asset Value, certain adjustments will be made to reduce inequities that could otherwise result to the subscriber or beneficiary of the Incentive Fee. For the financial period ended 30 June 2021 an equalisation credit of USD897,283 (30 June 2020: USD740,153) was applied by the Company.

11. Administration Fees and Depositary/Custodian Fees

The Company has appointed BNY Mellon Fund Services (Ireland) Designated Activity Company ("BNY Mellon") to act as Administrator, registrar and transfer agent and The Bank of New York Mellon SA/NV, Dublin Branch to act as Depositary (the "Depositary"). BNY Mellon is entitled to receive out of the assets of the Funds an annual administration fee, accrued and calculated on each dealing day and payable monthly in arrears of up to 0.105% of the aggregated Net Assets. BNY Mellon is also entitled to a shareholding services fee of USD1,875 per share class per month together with agreed upon transaction charges. The Administrator is also entitled to a financial reporting fee of up to USD5,000 per set of financial statements and other out of pocket expenses out of the assets of the Funds (plus VAT thereon if any).

The Administration fee accrued for the financial period ended 30 June 2021 was USD234,213 (30 June 2020: USD226,255) and the amount outstanding at 30 June 2021 was USD86,847 (30 June 2020: USD120,069).

The Depositary is entitled to an asset based fee of up to 0.02% per annum payable monthly together with sub-custodians' fees (which will be charged at normal commercial rates) as well as agreed upon transaction charges (which will be at normal commercial rates) and other out of pocket expenses (plus VAT thereon if any).

The Depositary fee accrued for the financial period ended 30 June 2021 was USD86,357 (30 June 2020: USD83,545) and the amount outstanding at 30 June 2021 was USD13,151 (30 June 2020: USD21,149).

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

12. Directors' Fees and Expenses

The Directors shall be entitled to a fee in remuneration for their services at a rate to be determined from time to time by the Directors, but so that the aggregate amount of each Director's remuneration in any one year shall not exceed €15,000 (30 June 2020: €15,000) or such higher amount as may be approved by resolution of the Directors and notified to shareholders. The Directors may also be paid all travelling, hotel and other expenses, properly incurred by them, in attending and returning from meetings of the Directors or general meetings of the Company or in connection with the business of the Company. The Directors may in addition to such remuneration as aforesaid grant special remuneration to any Director who, being called upon, shall perform any special or extra services to or at the request of the Company and such remuneration will be at normal commercial rates.

The Directors' fees and expenses accrued for the financial period ended 30 June 2021 was USD15,641 (30 June 2020: USD13,144) and the amount outstanding at 30 June 2021 was USD10,293 (30 June 2020: USD7,203).

13. Efficient Portfolio Management

The Company may enter into a variety of derivative instruments including, but not limited to, forward foreign exchange contracts, futures, options, swaps, contracts-for-difference, stock lending and repurchase agreements for the purposes of efficient portfolio management only, subject to the conditions and limits set out in the Central Bank (Supervision and Enforcement) Act 2013 (Section 48 (1)) (Undertakings for Collective Investment in Transferable Securities) Regulations 2019 (the "Central Bank UCITS Regulations") and within any further limits laid down by the Central Bank of Ireland from time to time. In particular, the Funds may engage in forward foreign exchange contracts to provide protection against exchange rate risks, including cross-currency hedging, and in order to hedge foreign currency exposure of the underlying assets of the Funds into the base currency of the Funds or into a currency institutionally linked to the base currency. It is intended that the use of such forwards may reduce the currency risk in respect of the Funds and will better enable the Funds to manage its assets and liabilities. Futures contracts may be used to hedge or gain exposure to an increase in the value of an asset, market, currency, or deposit. Options may be used to hedge or achieve exposure to a particular market instead of using a physical security. Swaps may be used to achieve profit as well as to hedge existing long positions. Contracts-for-difference ("CFDs") are bilateral agreements to exchange the difference between opening and closing contracts, which represent the performance of an underlying share.

At the discretion of the Directors, the Funds may use financial derivative instruments as a primary investment policy and details of the investment policy will be set out in the applicable Supplement in accordance with the requirements of the Central Bank of Ireland.

For the period ended 30 June 2021 and 30 June 2020, the Company has utilised forward foreign currency contracts. As at 30 June 2021, all derivatives are OTC derivatives. All open derivative positions are disclosed in the schedule of investments except for forward currency contracts which are disclosed in note 7 (d) above.

14. Directors' Interests, Connected Persons and Related Party Transactions

Fees payable to the relevant Investment Manager are disclosed in notes 9 and 10.

Depositary and Administrator

Although not deemed to be related parties under FRS 102 as they do not exercise "significant influence" over the activities of the Company, the Regulations also deem a "Depositary" and its "associated or group companies" to be "connected persons" to the Company. As such, The Bank of New York Mellon SA/NV, Dublin Branch, the Depositary, and BNY Mellon Fund Services (Ireland) Designated Activity Company, the Administrator, are connected persons to the Company.

The Board of Directors is satisfied that there are arrangements (evidenced by written procedures) in place, to ensure that any transaction carried out with the Company by a promoter, manager, depositary/custodian, investment manager and/or associated or group companies of these ("connected persons") are carried out as if negotiated at arm's length and that all such transactions are carried out in the best interests of the shareholders. The Board of Directors are satisfied that transactions with connected persons entered into during the period complied with the obligations set out in the Regulations.

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

14. Directors' Interests, Connected Persons and Related Party Transactions (continued)

30 June 2021			Number of
Key personnel	Role/Team	Fund/Class	Shares held
Lars Tell/Tellaviva AS	Director	Sector Healthcare Value Fund, Class A NOK	250
Trond Tviberg/Meditek Capital AS	Investment Manager, Sector Gamma AS	Sector Healthcare Value Fund, Class A NOK	8,976
Trond Horneland/ETHO AS	Investment Manager	Sector Healthcare Value Fund, Class A NOK	22,040
Sector Gamma AS	Investment Manager	Sector Healthcare Value Fund, Class B SEK	118
30 June 2020			NI I C
30 June 2020			Number of
Key personnel	Role/Team	Fund/Class	Shares held
	Role/Team Director	Fund/Class Sector Healthcare Value Fund, Class A NOK	
Key personnel			Shares held
Key personnel Lars Tell/Tellaviva AS	Director	Sector Healthcare Value Fund, Class A NOK	Shares held 181

As at 30 June 2021 and 30 June 2020, Sector Asset Management AS held 3 Class A EUR Shares, 2 Class A NOK Shares and 3 Class A USD Shares in Sector Healthcare Value Fund.

15. Contingent Liabilities

The Company is established as a segregated portfolio company. As a matter of Irish law, the assets of one Fund will not be available to satisfy the liabilities of another. However, the Company is a single legal entity which may operate or have assets held on its behalf or be subject to claims in other jurisdictions which may not necessarily recognise such segregation. There is no guarantee that the courts of any jurisdiction outside Ireland will respect the limitations on liability associated with segregated portfolio companies nor is there any guarantee that the creditors of one Fund will not seek to enforce such Fund's obligations against another Fund.

As at 30 June 2021 and 30 June 2021 there were no known contingent liabilities.

16. Soft Commission

There were no soft commissions for the financial period ended 30 June 2021 and 30 June 2020.

17. IMR Regulations

In response to the CBI publishing the Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) Investor Money Regulations 2015 for Fund Service Providers (the "Investor Money Regulations" or "IMR") issued in March 2015, subscription and redemption monies will (effective from 1 July 2016), be channeled through a sub-fund cash collection account in the name of the sub-fund. Pending issue of the shares and/or payment of subscription proceeds to an account in the name of the sub-fund(s), and pending payment of redemption proceeds or distributions, the relevant investor will be an unsecured creditor of the sub-fund in respect of amounts paid by or due to it. As at 30 June 2021 and 30 June 2020, the Funds had received subscriptions in advance and these amounts are reflected on the Balance Sheet.

18. Comparative Period

The prior period comparatives are for the financial period 1 January 2020 to 30 June 2020.

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

19. Three Period Historical Net Asset Value

The following tables outline the number of shares outstanding and the Net Asset Value per share for each share class for the last three reporting periods.

30 June 2021

50 June 2021	Howard Faulty Con	tow Haalthaawa
	Harvest Equity Sect Kernel	Value Fund
	USD	USD
Total Net Asset Value	USD	482,694,470
Total Net Asset Value		402,094,470
Shares outstanding		
Class A EUR	_	25,084
Class A NOK	_	76,221
Class A USD	_	61,126
Class B EUR	_	750
Class B NOK	_	501,631
Class B SEK	_	21,144
Class B USD	_	301,667
Class X EUR	_	309,159
Class X USD	_	268,705
Class E NOK	_	310,166
Class E USD	_	15,000
Class Y EUR	_	40,521
Class Y GBP	_	621,295
Class Y USD	_	501,311
Net Asset Value per Share		
Class A EUR	_	344.65
Class A NOK	_	3,083.07
Class A USD	_	518.15
Class B EUR	_	145.52
Class B NOK	_	1,683.62
Class B SEK	_	1,596.89
Class B USD	_	170.00
Class X EUR	_	111.92
Class X USD	_	178.33
Class E NOK	_	107.20
Class E USD	_	102.18
Class Y EUR	_	118.77
Class Y GBP	_	119.06
Class Y USD	_	115.13

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

19. Three Period Historical Net Asset Value (continued)

31 December 2020

Class B USD

Class P NOK

Class P NOK Unhedged

31 December 2020		
	Harvest Equity Sec Kernel	Value Fund
Total Net Asset Value	USD 124,692,469	USD 367,309,862
Change outstanding		
Shares outstanding Class A EUR		11,959
Class A NOK	104,603	77,368
Class A USD	164	65,122
Class B EUR	104	2,107
Class B NOK	_	490,694
Class B SEK	_	16,371
Class B USD	_	187,407
Class P NOK	640,165	107,407
Class P NOK Unhedged	227,923	_
Class P USD	327	_
Class X EUR		309,159
Class X USD	_	176,532
Class Y EUR	_	39,316
Class Y GBP	_	479,279
Class Y USD	_	419,660
Net Asset Value per Share		
Class A EUR		315.87
Class A NOK	1,096.67	2,823.79
Class A USD	143.30	474.05
Class B EUR	143.50	133.94
Class B NOK	_	1,544.85
Class B SEK	_	1,468.78
Class B USD	_	155.66
Class P NOK	1,032.92	-
Class P NOK Unhedged	1,276.70	_
Class P USD	166.26	_
Class X EUR	=	102.27
Class X USD	_	162.20
Class Y EUR	_	105.19
Class Y GBP	_	105.40
Class Y USD	_	104.59
30 June 2020		
	Harvest Equity Sec	ctor Healthcare
	Kernel	Value Fund
	USD	USD
Total Net Asset Value	131,895,441	208,904,086
Shares outstanding		
Class A EUR	_	14,088
Class A NOK	90,583	77,121
Class A USD	7	61,695
Class B EUR	_	1,685
Class B NOK	_	506,697
Class B SEK	_	14,648
Class B LICD		00 (40

671,744

439,973

88,640

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

NOTES TO THE FINANCIAL STATEMENTS (Continued)

19. Three Period Historical Net Asset Value (continued)

30 June 2020

	Harvest Equity Sector Healthcare	
	Kernel	Value Fund
	USD	USD
Class P USD	327	_
Class X EUR	_	309,159
Class X USD	_	215,666
Net Asset Value per Share		
Class A EUR	_	293.43
Class A NOK	1,002.53	2,633.16
Class A USD	125.07	437.61
Class B EUR	_	125.28
Class B NOK	_	1,444.82
Class B SEK	_	1,373.38
Class B USD	_	144.65
Class P NOK	939.46	_
Class P NOK Unhedged	1,250.17	_
Class P USD	144.49	_
Class X EUR	_	94.96
Class X USD	-	148.99

20. Significant Events during the financial period

Upon recommendation from the Investment Manager, Harvest Funds AS, the Directors resolved to terminate Harvest Equity Kernel, with effect from 15 January 2021. The Directors will seek revocation of the approval of the Fund from the Central Bank of Ireland.

On 5 February 2021, Harvest Funds AS resigned as Investment Manager and with immediate effect Sector Funds Services AS was appointed as the Investment Manager.

A revised supplement for Sector Healthcare Value Fund was noted by the Central Bank of Ireland on 3 March 2021.

A revised supplement for Sector Healthcare Value Fund was noted by the Central Bank of Ireland on 18 May 2021.

Effective 21 May 2021, Sector Sigma Nordic Fund's authorisation was revoked by the Central Bank of Ireland.

Market disturbances

The global public health crisis which arose from the outbreak of the novel coronavirus disease (known as COVID-19) has caused considerable volatility and disruption in financial markets since early March 2020. It is unknown what the impact will be on the global economy but the uncertainty and instability from COVID-19 for a prolonged period could have an adverse impact on the Company's or relevant Fund's business, opportunities, operations, financial condition and cash flows and there can be no assurance that the risks associated with COVID-19 will not alter significantly the attractiveness of an investment in the Company or a Fund as a result of the potential for capital losses and general uncertainty.

There were no other significant events during the period.

21. Significant Events after the Balance Sheet Date

There were no significant events after the balance sheet date.

22. Approval of Financial Statements

The financial statements were authorised for issue by the Directors on 23 August 2021.

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

SIGNIFICANT PORTFOLIO MOVEMENTS

In accordance with the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48 (1) (Undertakings for Collective Investment in Transferable Securities) Regulations, 2019, a statement of the largest changes in the composition of the Schedule of Investments during the period is provided to ensure that the shareholders can identify changes in the investments held by the Fund. These statements present the aggregate purchases and sales of an investment, exceeding 1% of the total value of purchases and sales for the period. At a minimum the largest 20 purchases and sales are listed. If the Fund enters into less than 20 purchases or sales during the year, then all transactions are presented.

Harvest Equity Kernel

LARGEST PURCHASES	COST
	\$
GlaxoSmithKline Plc	11,580
LARGES T SALES	PROCEEDS
	\$
Samsung Electronics Co., Ltd.	2,183,372,840
Azbil Corp.	324,727,042
Tokyo Electron Ltd.	195,746,844
Sony Group Corp.	178,356,822
Murata Manufacturing Co., Ltd.	170,665,361
Nintendo Co Ltd	125,373,921
Ono Pharmaceutical Co., Ltd.	121,710,355
TIS, Inc.	118,549,186
NEC Corp.	112,825,431
SCSK Corp.	108,864,224
KDDI Corp.	100,332,530
United Microelectronics Corp.	65,698,335
Taiwan Semiconductor Manufacturing Co., Ltd.	45,229,694
Wistron Corp.	29,773,831
China Conch Venture Holdings Ltd.	10,767,459
Tencent Holdings Ltd.	9,164,809
Telefonaktiebolaget LM Ericsson	9,163,273
Assa Abloy AB	8,832,043
Goldman Sachs US\$ Treasury Liquid Reserves Fund	8,000,000
China Medical System Holdings Ltd.	5,840,857

Unaudited Interim Financial Statements For the financial period 1 January 2021 to 30 June 2021

SIGNIFICANT PORTFOLIO MOVEMENTS (Continued)

Sector Healthcare Value Fund

LARGEST PURCHASES	COST \$
Goldman Sachs US\$ Treasury Liquid Reserves Fund	18,701,882
Pfizer, Inc.	17,559,390
GlaxoSmithKline Plc	13,332,955
Bristol-Myers Squibb Co.	12,660,607
Merck & Co., Inc.	10,912,395
Baxter International, Inc.	9,752,644
UCB S.A.	9,137,107
Organon & Co.	8,711,605
Biogen, Inc.	8,672,674
Gilead Sciences, Inc.	8,587,945
Henry Schein, Inc.	8,382,710
BioM arin Pharmaceutical, Inc.	8,175,369
Johnson & Johnson	7,328,878
Novartis AG	6,840,501
Eisai Co. Ltd.	6,132,629
Ionis Pharmaceuticals, Inc	5,474,016
Centene Corp.	5,071,316
Qiagen NV	4,685,565
Hologic, Inc.	4,570,185
H Lundbeck A/S	4,381,261
	1,501,201
LARGES T S ALES	PROCEEDS
	\$
Goldman Sachs US\$ Treasury Liquid Reserves Fund	\$ 12,701,882
Goldman Sachs US\$ Treasury Liquid Reserves Fund Alexion Pharmaceuticals, Inc.	\$ 12,701,882 11,359,294
Goldman Sachs US\$ Treasury Liquid Reserves Fund Alexion Pharmaceuticals, Inc. Abbott Laboratories	\$ 12,701,882 11,359,294 10,931,476
Goldman Sachs US\$ Treasury Liquid Reserves Fund Alexion Pharmaceuticals, Inc. Abbott Laboratories Gilead Sciences, Inc.	\$ 12,701,882 11,359,294 10,931,476 10,303,613
Goldman Sachs US\$ Treasury Liquid Reserves Fund Alexion Pharmaceuticals, Inc. Abbott Laboratories Gilead Sciences, Inc. Merck KGaA	\$ 12,701,882 11,359,294 10,931,476 10,303,613 8,404,055
Goldman Sachs US\$ Treasury Liquid Reserves Fund Alexion Pharmaceuticals, Inc. Abbott Laboratories Gilead Sciences, Inc. Merck KGaA Johnson & Johnson	\$ 12,701,882 11,359,294 10,931,476 10,303,613 8,404,055 7,997,923
Goldman Sachs US\$ Treasury Liquid Reserves Fund Alexion Pharmaceuticals, Inc. Abbott Laboratories Gilead Sciences, Inc. Merck KGaA Johnson & Johnson Merck & Co Inc	\$ 12,701,882 11,359,294 10,931,476 10,303,613 8,404,055 7,997,923 7,783,429
Goldman Sachs US\$ Treasury Liquid Reserves Fund Alexion Pharmaceuticals, Inc. Abbott Laboratories Gilead Sciences, Inc. Merck KGaA Johnson & Johnson Merck & Co Inc Novartis AG	\$ 12,701,882 11,359,294 10,931,476 10,303,613 8,404,055 7,997,923 7,783,429 7,030,442
Goldman Sachs US\$ Treasury Liquid Reserves Fund Alexion Pharmaceuticals, Inc. Abbott Laboratories Gilead Sciences, Inc. Merck KGaA Johnson & Johnson Merck & Co Inc Novartis AG HCA Holdings, Inc.	\$ 12,701,882 11,359,294 10,931,476 10,303,613 8,404,055 7,997,923 7,783,429 7,030,442 6,815,110
Goldman Sachs US\$ Treasury Liquid Reserves Fund Alexion Pharmaceuticals, Inc. Abbott Laboratories Gilead Sciences, Inc. Merck KGaA Johnson & Johnson Merck & Co Inc Novartis AG HCA Holdings, Inc. LivaNova Plc	\$ 12,701,882 11,359,294 10,931,476 10,303,613 8,404,055 7,997,923 7,783,429 7,030,442 6,815,110 6,503,916
Goldman Sachs US\$ Treasury Liquid Reserves Fund Alexion Pharmaceuticals, Inc. Abbott Laboratories Gilead Sciences, Inc. Merck KGaA Johnson & Johnson Merck & Co Inc Novartis AG HCA Holdings, Inc. LivaNova Plc Sanofi	\$ 12,701,882 11,359,294 10,931,476 10,303,613 8,404,055 7,997,923 7,783,429 7,030,442 6,815,110 6,503,916 6,342,574
Goldman Sachs US\$ Treasury Liquid Reserves Fund Alexion Pharmaceuticals, Inc. Abbott Laboratories Gilead Sciences, Inc. Merck KGaA Johnson & Johnson Merck & Co Inc Novartis AG HCA Holdings, Inc. LivaNova Ple Sanofi BioNTech SE	\$ 12,701,882 11,359,294 10,931,476 10,303,613 8,404,055 7,997,923 7,783,429 7,030,442 6,815,110 6,503,916 6,342,574 5,568,510
Goldman Sachs US\$ Treasury Liquid Reserves Fund Alexion Pharmaceuticals, Inc. Abbott Laboratories Gilead Sciences, Inc. Merck KGaA Johnson & Johnson Merck & Co Inc Novartis AG HCA Holdings, Inc. LivaNova Plc Sanofi	\$ 12,701,882 11,359,294 10,931,476 10,303,613 8,404,055 7,997,923 7,783,429 7,030,442 6,815,110 6,503,916 6,342,574 5,568,510 5,510,191
Goldman Sachs US\$ Treasury Liquid Reserves Fund Alexion Pharmaceuticals, Inc. Abbott Laboratories Gilead Sciences, Inc. Merck KGaA Johnson & Johnson Merck & Co Inc Novartis AG HCA Holdings, Inc. LivaNova Plc Sanofi BioNTech SE Astellas Pharma, Inc . GlaxoSmithKline Plc	\$ 12,701,882 11,359,294 10,931,476 10,303,613 8,404,055 7,997,923 7,783,429 7,030,442 6,815,110 6,503,916 6,342,574 5,568,510 5,510,191 5,341,796
Goldman Sachs US\$ Treasury Liquid Reserves Fund Alexion Pharmaceuticals, Inc. Abbott Laboratories Gilead Sciences, Inc. Merck KGaA Johnson & Johnson Merck & Co Inc Novartis AG HCA Holdings, Inc. LivaNova Plc Sanofi BioNTech SE Astellas Pharma, Inc. GlaxoSmithKline Plc Bristol-Myers Squibb Co.	\$ 12,701,882 11,359,294 10,931,476 10,303,613 8,404,055 7,997,923 7,783,429 7,030,442 6,815,110 6,503,916 6,342,574 5,568,510 5,510,191 5,341,796 4,831,760
Goldman Sachs US\$ Treasury Liquid Reserves Fund Alexion Pharmaceuticals, Inc. Abbott Laboratories Gilead Sciences, Inc. Merck KGaA Johnson & Johnson Merck & Co Inc Novartis AG HCA Holdings, Inc. LivaNova Plc Sanofi BioNTech SE Astellas Pharma, Inc. GlaxoSmithKline Plc Bristol-Myers Squibb Co. BioMarin Pharmaceutical, Inc.	\$ 12,701,882 11,359,294 10,931,476 10,303,613 8,404,055 7,997,923 7,783,429 7,030,442 6,815,110 6,503,916 6,342,574 5,568,510 5,510,191 5,341,796 4,831,760 4,746,521
Goldman Sachs US\$ Treasury Liquid Reserves Fund Alexion Pharmaceuticals, Inc. Abbott Laboratories Gilead Sciences, Inc. Merck KGaA Johnson & Johnson Merck & Co Inc Novartis AG HCA Holdings, Inc. LivaNova Ple Sanofi BioNTech SE Astellas Pharma, Inc . GlaxoSmithKline Plc Bristol-Myers Squibb Co. BioMarin Pharmaceutical, Inc. Boston Scientific Corp.	\$ 12,701,882 11,359,294 10,931,476 10,303,613 8,404,055 7,997,923 7,783,429 7,030,442 6,815,110 6,503,916 6,342,574 5,568,510 5,510,191 5,341,796 4,831,760 4,746,521 4,556,579
Goldman Sachs US\$ Treasury Liquid Reserves Fund Alexion Pharmaceuticals, Inc. Abbott Laboratories Gilead Sciences, Inc. Merck KGaA Johnson & Johnson Merck & Co Inc Novartis AG HCA Holdings, Inc. LivaNova Plc Sanofi BioNTech SE Astellas Pharma, Inc . GlaxoSmithKline Plc Bristol-Myers Squibb Co. BioMarin Pharmaceutical, Inc. Boston Scientific Corp. Biogen, Inc.	\$ 12,701,882 11,359,294 10,931,476 10,303,613 8,404,055 7,997,923 7,783,429 7,030,442 6,815,110 6,503,916 6,342,574 5,568,510 5,510,191 5,341,796 4,831,760 4,746,521 4,556,579 4,412,592
Goldman Sachs US\$ Treasury Liquid Reserves Fund Alexion Pharmaceuticals, Inc. Abbott Laboratories Gilead Sciences, Inc. Merck KGaA Johnson & Johnson Merck & Co Inc Novartis AG HCA Holdings, Inc. LivaNova Ple Sanofi BioNTech SE Astellas Pharma, Inc . GlaxoSmithKline Plc Bristol-Myers Squibb Co. BioMarin Pharmaceutical, Inc. Boston Scientific Corp.	\$ 12,701,882 11,359,294 10,931,476 10,303,613 8,404,055 7,997,923 7,783,429 7,030,442 6,815,110 6,503,916 6,342,574 5,568,510 5,510,191 5,341,796 4,831,760 4,746,521 4,556,579